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Human Eye development 
Eye formation begins after the third week of gestation with the optic sulci and 
ends with foveal maturation 3 to 4 years after birth. 
The eye development begins around day 22 with the formation of the optic 
sulci in the inner aspect of the neuronal plate. The optic sulci will evaginate to 
form the optic vesicles. At day 27, a thickening of the neural ectoderm becomes 
the lens placode, which coincides with the formation of a constriction in the optic 
vesicle, the future optic stalk. The invagination of the optic vesicle will form a 
double wall optic cup where the inner layer (retinal disk) will lead to the forma-
tion of the neuro-retina and the outer layer to the formation of the future retinal 
pigment epithelium (RPE). By day 36, a lens vesicle separates from the lens 
placode that will eventually become the lens and the cornea respectively. The 
longitudinal groove of the optic stalk will allow the formation of the hyaloid ar-
tery, but will progressively close around 6 weeks.1 At 8 weeks, mesenchyme 
derived from the neural crest, will condense around the external surface of the 
optic cup. The inner condensation adjacent to the RPE will form the future chor-
oid and the outer condensation will become the future sclera. At this stage, the 
developing eye has a diameter of 1.5 to 2 mm.1-3. 
(See Figure 1) 
At 6 weeks the neuro-retina is composed of an outer nuclear layer and an 
inner acellular layer. At 7 weeks, it will be composed of an inner nuclear layer 
named the inner neuroblastic layer that is separated from the outer neuroblastic 
layer by an acellular zone which is called the transient layer of Chievitz4 (TLC). 
By 11 weeks the TLC will disappear, and the inner nuclear layer containing the 
cell bodies of amacrine and Müller cells will appear. Shortly afterwards, the 
bipolar and horizontal cells differentiate from the outer neuroblastic layer. At 4 
months, the outer neuroblastic layer will become the photoreceptor nuclei form-
ing the outer nuclear layer and their axons will lead to the outer plexiform layer. 
Further landmarks in retinal development will occur and consist in synapto-
genesis horizontal cell formation and invasion of the retina by microglia around 
5 months. Maculogenesis begins around 4 to 5 months by first an increase in 
ganglion cell layers up to 8 layers at 6 months. At 7 months, the foveal depres-
sion appears due to the lateral displacement of the ganglion cell layer. At birth 
there is only one layer of ganglion cells left and 4 months postpartum both gan-
glion cell and inner nuclear layers have withdrawn to the edge of the fovea leav-
ing only cone nuclei in the foveal region. The macula will need another few 
years to reach maturation.5 
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Figure 1. Embryology of the 
eye (Adapted from John For-
rester et al. The Eye Basic 
Sciences in Practice, Ed 
Saunders) 
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PAX6 in conjunction with other genes such as Sox2 and Otx2 cooperatively 
control each stage of eye development (See Figure 2).6 
PAX6 is also required for all aspects of lens development, including its final 
differentiation and control of crystallin expression, although the crystallin origi-
nates from non-neural tissue.7 
 
Figure 2. PAX6, SOX2 and OTX2 
role in organ induction during eye 
formation (From Hever AM et al. Clin 
Genet 2006). 
PAX Family 
The Paired box (PAX) genes are members of the family of tissue specific tran-
scription factors. They are all containing a paired domain and usually also a 
partial or complete homeodomain. An octapeptide may sometimes be as well 
present.8 
The PAX gene family plays a critical role in the formation of tissues and organs 
during embryonic development. For example, in the eye, PAX6 gene has been 
called the master gene for eye development.9,10. 
I n t r o d u c t i o n  
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The PAX gene family is also important for maintaining the normal function of 
certain cells after birth such as myoblasts, pineal glande and the eye.11,12 To 
carry out these roles, the PAX genes provide instructions for making proteins 
that attach to specific areas of DNA and help control the expression of specific 
genes. On the basis of this action, PAX proteins are called transcription factors. 
After birth, the PAX genes are usually turned off (inactivated), but in some tis-
sues the PAX genes can remain to be active. These active genes play a role in 
tissue re-growth, maintaining of cyto-architecture and protection against cell 
death caused by cellular stress.13,14 There are nine genes in the PAX gene fam-
ily. These genes are divided into groups based on various aspects of similar-
ity.15-17 
– PAX group 1 (PAX 1 and PAX 9).18-20 
– PAX group 2 (PAX 2, PAX5 and PAX 8).21-23 
– PAX group 3 (PAX 3 and PAX 7).24 
– PAX group 4 (PAX 4 and PAX 6).25-30 
Mutations in PAX genes lead to disorders that involve the incomplete develop-
ment of tissues in which a particular PAX gene is expressed. For example, 
Pax8 homozygous deficient mice display dysgenesis of the thyroid gland includ-
ing loss of all follicular cells.31 Additionally, the overexpresion of PAX genes has 
been noted in a variety of cancers.24-32,33 Moreover, it is thought that PAX genes 
confer cell protection and prevent cell death and also allows cell proliferation.34 
More specifically, overexpresion of Pax6 gene leads to induction of ectopic sur-
numerous eyes in the Drosophila and Xenopus laevis.35,36,37 
In this thesis we will refer to international nomenclature of genes and protein for 
human and mice as follow.38 
– Human gene: PAX6 (All in upper case and all italic) 
– Human protein: PAX6 (All in upper case, not in italic) 
– Mouse gene: Pax6 (First letter in upper case and all in italic) 
– Mouse protein: PAX6 (All in upper case, not in italic) 
One will note that human and mouse protein PAX6 are identically written, there-
fore, if the context does not allow to make the distinction between them, we 
would specify in the text whether it is a mouse or human PAX6 protein. 
PAX6 Gene 
PAX6 is a member of the PAX family genes that intervene in the formation of 
organs, tissues and cells during embryonic development. They code for highly 
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conserved DNA-binding proteins, transcriptor factors, alleged to be important for 
the control of expression and activity of several genes39 through attachment to 
specific areas of the DNA. PAX gene plays also a role in the maintenance and 
function of certain cells after birth such as corneal epithelial cells for PAX6.40,41 
This gene encodes paired box gene 6, one of many human homologues of the 
Drosophila melanogaster gene prd. During development PAX6 gene/ PAX6 
protein are involved in the formation of specific organs such as the pancreas, 
the spinal cord, the brain, the olfactory bulb and the eye.28-30,42,43 
Heterozygous mutations in this gene are known to cause several ocular disor-
ders the most common being aniridia.27,44 Null mutation of PAX6 results in cen-
tral nervous system abnormalities and anophthalmia and is lethal before birth 
except only one patient has been reported to survive until 8 days after birth.45 
PAX6 was identified as a candidate aniridia gene during the search for the 
genes responsible for the WAGR syndrome (Wilms tumor, aniridia, genitouri-
nary malformations, and mental retardation, which is caused by hemizygous 
deletions of 11p13).46 
This gene was first cloned in the mouse and shortly thereafter in humans.47 
The mouse mutants of this gene called small eye gene and the aniridia gene in 
humans, called the aniridia gene are homologous.47,48 The human PAX6 sur-
prisingly turned out to correspond to the Drosophila eyeless (ey) gene. This 
gene shows extensive sequence similarity, both in the paired domain (94% 
identity), and in the homeodomain (90% identity) with human PAX6 gene.49-55 
The fact that small eye, aniridia, and eyeless share mutations in homologous 
genes and the paramount role of PAX6 in eye formation explain the other des-
ignation given to PAX6: “the master gene” for eye formation in both vertebrates 
and invertebrates.9,10 
Localization of the PAX6 gene 
The PAX6 gene is located on the short (p) arm of chromosome 11 at band13. 
(Figure 3) More precisely, the PAX6 gene is located from base pair 31,767,033 
to base pair 31,789,454 on chromosome 11. It has a size of 22,422 bases. 
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Figure 3. Localization of PAX6 on Chromosome 11 (From Genetic Home
Reference, http://ghr.nlm.nih.gov/dynamicImages/chromomap/pax6.jpeg) 
 
PAX6 gene is composed of 14 exons and 13 introns.46 There is a CCAGCATGC 
translation start site in exon 4 and a TTA stop codon in exon 13. (See figure 4 
and 5 below). 
 
 
Figure 4. PAX6  (From AL Friedman et Al. Journal of Young investigators, 1998). 
 
 
Figure 5.PAX6 sequence. (From Glaser et Al. Nature Genetics 1992). 
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PAX6 contains an alternative mRNA splice-site in the paired domain that can 
result in a 42-nucleotide insertion. Alternative splicing of PAX6 generates a 
major isoform, PAX6(+5a) that exhibits different DNA-binding properties due to 
a 14 amino acid insertion in the amino-terminal region of the PRD domain that 
unmasks binding properties of the C-terminal subregion.56 PAX6 levels are up 
to 10 times that of PAX6(+5a) in the eye during development and after birth. 
This ratio is crucial for proper ocular development and also for maintenance of 
eye structures in adulthood.57,58 The two isoforms synergistically activate some 
gene promoters suggesting a cooperative function between these two proteins 
in the adult eye.59 
PAX6 Protein 
The PAX6 protein is composed of a sequence of 422 amino acids. (See Figure 
6). Its isoforms PAX6 (5A) contains 14 additional amino acids inserted in the 
pair domain.60 PAX6 protein is essential as a transcription factor in the devel-
opment of the eye, nose, central nervous system and pancreatic islet alpha 
cells. 
Figure 6. Primary structure of PAX6 protein composed of 422 AA.  
(From Adam A. L. Friedman. Journal of Young investigators, 1998). 
 
The PAX6 protein is composed of two DNA-binding domains, a paired domain 
(PD) at the N terminus and a paired-like homeodomain (HD) that are linked by a 
glycine-rich domain (the linker) and a transactivation region (PST), which is rich 
in proline, serine, and threonine amino acids at the C terminus of the PAX6 
protein (see Figure 7A).10 
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Figure 7. Structure of the PAX6 protein (From A.Tsonis et Al. Experimental Eye Research, 2006). 
 
The secondary structure of PAX6 protein has been highlighted by biochemical 
and crystallographic studies. These studies showed that the PD is composed of 
two independent subdomains at the N-terminal (N subdomain) and C-terminal 
(C-subdomain) respectively (see Figure 7B). The N subdomain (residues 1–60) 
contains a short β motif and three α helices while the C subdomain (77–133) 
contains three α helices. In both domains, the three α helices fold like in the 
homeodomain. The homeodomain is also composed of three α helices that fold 
together. No protein-protein contact between both N and C subdomain has 
been demonstrated. Sequence comparisons show that the N subdomain is 
highly conserved among species.61 There is 68% homology for residues 1–60 
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between human and Drosophila PAX6 protein. These α and β motifs create 
major and minor groove in the protein structure that allows DNA attachments 
and interactions. In this way PAX6 protein exerts its role as a transcription factor 
on other genes. Through DNA binding, PAX6 controls the expression of various 
downstream target genes involved in complex gene regulatory networks for cell 
proliferation, adhesion, migration, and neurogenesis.62-64 
 
The alternatively spliced form of PAX6, PAX6–5a, contains an additional 14 
amino acids in the PD which disrupts the N subdomain and alters DNA binding 
properties. The PDs of other genes of the PAX family, the PAX2, PAX3, and the 
binding sequence of PAX-5 (BSAP), and PAX6 proteins can recognize similar 
DNA sequences.65-67 Several target genes have been identified.39 PAX6 protein 
expression continues in the adult retina, lens, and cornea and may help to 
maintain good ocular health.39-68 Three isoforms of PAX6 protein are derived 
through alternative splicing (PAX6-ex12, PAX6–5a,6’, PAX6–5a). The ratios of 
these isoforms may be critical to normal ocular development as discussed ear-
lier.69 
Human PAX6 Mutations 
Homozygous PAX6 Mutations 
Human PAX6−/− homozygous mutations are very rare and the condition is le-
thal before or shortly after birth causing anophthalmia with severe craniofacial 
and central nervous system defects. To our knowledge, only 2 cases of PAX6 -
/- mutations have been reported. 
One report by Hodgson et al described a baby girl who had both parents af-
fected by aniridia. She died before birth at 37 weeks of gestation and had no 
eyes, no palpebral fissures and nasal bones were absent. She disclosed severe 
CNS malformations and no adrenal glands.70 
Glaser et al in 1994, who were the first one to describe the PAX6 gene, de-
scribed a second patient with PAX6-/- homozygous mutation. The baby sur-
vived until 8 days after birth but presented with bilateral anophthalmia, micro-
cephalia and agenesis of the corpus callosum.45 (See Figure 8) 
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Figure 8. Anophthalmia 
(From Glaser et Al, Nature Genetics, 1994) 
PAX6 
Heterozygous PAX6 +/- mutations can lead to a variety of different ocular phe-
notypes comprising anterior or posterior segment anomalies and optic nerve 
malformations as well. The most frequent abnormality is aniridia. Others condi-
tions include: autosomal dominant keratitis, Peters anomaly, juvenile cataract, 
glaucoma, isolated foveal hypoplasia, microphthalmia ectopia pupillae, optic 
disc coloboma, optic nerve hypoplasia and morning glory disc anomaly and 
unusual ophthalmic phenotype associated with neurodevelopmental abnormali-
ties.71 
Of the many PAX6 mutations causing aniridia, most lead to loss of protein 
function and comprise nonsense mutations, splice mutations frameshifting dele-
tions and insertions, inframe insertions and deletions, missense mutations, and 
run-on mutations.27,72 
Of the 29 known mutations for non-aniridia eye disorders, 69% are mis-
sense mutations.72 
 
Table 1. Disease / Phenotype correlation 
Disease / phenotype Number of PAX6 Mutations  
Aniridia 196  
Optic-nerve Malformations  10  
Foveal Hypoplasia   3  
Peter’s anomaly   2  
Cataract, secondary glaucoma   1  
Cataract, with Nystagmus   1  
C h a p t e r  1  
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Disease / phenotype Number of PAX6 Mutations  
Ectopia pupillae   1  
Gillepsie syndrome   1  
Kertatitis, autosoma dominant   1  
Nystagmus   1  
Ocular anterior segment anomaly   1  
Absence of pineal gland   1  
WAGR syndrome   1  
From The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff 
 
Table 2. Different mutations of PAX6 gene 
Mutation type Number of PAX6 Mutations  
Missense / nonsense  87  
Splicing  32  
Regulatory   0  
Small deletions  58  
Small insertions  21  
Smal indels  11  
Gross deletions   9  
Gross insertions   2  
Complex rearrangements   3  
Repeat variations   0  
Total 223  
From The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff 
http://www.hgmd.cf.ac.uk 
Autosomal Dominant Keratitis 
Autosomal dominant keratitis (ADK) is an eye disorder consisting in corneal 
stroma opacification and vascularization of the peripheral cornea. It can be as-
sociated with foveal hypoplasia. ADK is inherited as a fully penetrant autosomal 
dominant disease with variable clinical presentation.73 Incorrect splicing and 
resulting truncation of PAX6 proline-serine-threonine activation domain has 
been shown to be the cause of autosomal dominant keratitis.74 Stem cell defi-
ciency associated with keratitis is also dependant of PAX6 mutation.75 (See 
Figure 9) 
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Figure 9. Autosomal Dominant Keratitis (From Mirzayans et Al. Am J Hum Genet. 1995). 
Peters syndrome or Peters’ anomaly 
In 1906, Peters described an association of signs consisting of white cornea 
absence of posterior corneal stroma, absence of Descemet membrane and 
irido-corneal synechia. The condition is now part of a group of ocular abnormali-
ties named anterior segment dysgenesis and include the cornea,the iris, the 
irido-corneal angle and the lens. A PAX6 gene missense mutation has been 
found in some patients.76,77 PAX6 intervenes in the formation of the neuronal 
crests that would later become the corneal stroma, Descemet membrane, the 
corneal endothelial, the irido-corneal angle and vitreous stroma (See Figure 10). 
In Peters’ anomaly there is a defect in the neuronal crest explaining its specific 
ocular phenotype.78 In certain cases, this syndrome is inherited and therefore 
genetic counselling is indicated.79 
 
 
Figure 10. Peters’ Anomaly (From Internet Journal of Ophthalmology 2003) 
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Aniridia 
Aniridia is a congenital, bilateral, panophtalmic condition. It is a rare disease 
that occurs with an incidence of 1:64,000 in the USA to 1:76,000 in Norway.80 
The disorder is characterized by the complete or partial absence of the iris and 
iris hypoplasia.81 Aniridia can be isolated or found in association with a range of 
other ophthalmological abnormalities including cataracts, glaucoma, corneal 
pannus.82 optic nerve hypoplasia, absence of macular reflex, ectopia lentis, 
nystagmus, and photophobia.83 Foveal and optic nerve hypoplasia are often 
present, causing a reduction in visual acuity and congenital sensory nystagmus. 
Progressive worsening of vision may occur later in life as a result of cataracts, 
glaucoma, and corneal opacification. A less common form of aniridia occurs in 
which the iris defects predominate, but visual acuity remains relatively unim-
paired. (See Figure 11) 
 
 
 
Figure 11. Aniridia (From Neethirajan et al. BMC Medical Genetics 2004) 
 
Aniridia may be familial or sporadic. Approximately 85% of cases are familial 
disclosing autosomal dominant inheritance with complete penetrance but vari-
able expressivity. These familial cases usually have isolated ocular involvement 
and are caused by mutation of PAX6 gene or deletion of a regulatory region 
controlling its expression. 
The 15% of cases that are sporadic84 usually present with a deletion on the 
short arm of chromosome 11 involving both PAX6 and the WT1 gene (which is 
located 700 kb telomerically from PAX6) resulting in the Wilm’s tumor, bilateral 
sporadic aniridia, genitourinary abnormalities and mental retardation (WAGR) 
syndrome.85 Individuals with deletion of PAX6 and WT1 have up to 50% risk of 
developing Wilms tumor. WAGR syndrome is the most common syndrome as-
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sociated with aniridia.86 Wilm’s tumor associated with genitourinary and renal 
abnormality is related to hemizygosity for Wilm’s tumor suppressor gene WT1, 
whereas ocular defects result from hemizygosity for the PAX6 gene.87 The as-
sociation between aniridia and Wilms tumor is referred to as Miller syndrome. 
Children disclosing Wilms tumor have 1.4% chance of having aniridia compared 
to 1 in 64000 in the general population. Miller syndrome has been attributed to a 
deletion of band 11p13. Patients with sporadic aniridia should undergo a thor-
ough physical examination and workup by a paediatrician. 
There is a correlation between the level of PAX6 activity and the severity of 
the aniridia phenotype.46 
While the majority of cases of aniridia are the result of PAX6 mutation, there 
are about 10% of reported cases with no identified mutation of PAX6.88 These 
patients preserve their visual function and may be therefore associated to a less 
severe phenotype of aniridia.89 
Foveal Hypoplasia 
Foveal hypoplasia is a condition in which the fovea is underdeveloped. It is 
characterized by the absence of foveal pigmentation and/or the foveal avascular 
zone. It may occur in isolation or in association with other conditions such as 
aniridia, albinism, achromatopsia, microphthalmia, retinopathy of prematurity 
(ROP), myopia and incontinentia pigmenti (IP).90-93 
One family was found to show isolated foveal hypoplasia related to PAX6 
missense mutation. The mutation occurred in the C-terminal domain of the gene 
whilst most of anterior segments anomalies were reported in the N-terminal 
domain.94 
Another splice mutation of PAX6 was found in a family with foveal hypopla-
sia, congenital nystagmus and anterior segment abnormalities such as iris hy-
poplasia or atypical coloboma.95 (See Figure 12) 
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Figure 12. Isolated Hypoplasia ( From Querques G et al. Retina 2008). 
Ectopia Pupillae 
Ectopia pupillae is a congenital eye malformation in which the pupils are dis-
placed from their normal central position. Missense mutation of PAX6 was 
found in a child disclosing ectopia pupillae as a prominent sign. Ectopia pupillae 
and aniridia were reported in patients with a truncation mutation of the PAX6 
gene.96 
 
 
Figure 13. Ectopia Pupillae (From Hanson et al. Human Mol Genet 1999). 
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Optic nerve malformations and PAX6 mutations 
A study described PAX6 missense mutations among European and Japanese 
patients with optic nerve malformations.97 This study identified novel mutations 
in eight pedigrees with optic-nerve malformations, including coloboma Morning 
glory disc anomaly, optic-nerve hypoplasia/aplasia, and persistent hyperplastic 
primary of the vitreous. PAX6 is expressed in the CNS, the optic stalk, the retinal 
progenitor cells and retina ganglion cells during development. Interestingly, the 
disease-causing events of optic-nerve malformation—include embryonic fissure 
(coloboma), retinal ganglion cells (ONH/aplasia) and the lamina cribosa (Morning 
glory disc anomaly).97,98 
Optic nerve coloboma 
Optic nerve coloboma is a congenital condition caused by incomplete closure of 
the embryonic fissure. PAX6 missense mutation does not allow proper closure 
of the embryonic fissure during development. Typical optic disc colobomas are 
infero-nasal and range from a hugely excavated disc to a subtle change in the 
retinal pigment epithelium. Optic disc coloboma can be found with chorioretinal 
coloboma and or iris coloboma. This affection might be isolated or associated 
with other ocular abnormalities or brain anomalies.99 
Optic nerve hypoplasia 
Optic nerve hypoplasia occurs before the end of ocular development and is 
associated with a decrease of retina ganglion cell axons. It consists in a re-
duced size optic disc, diminished number of axons, a small or absent cup, an 
increase in the tortuosity of the retinal vessels with fewer than normal branching 
points, and the presence of peripapillary abnormalities. There is a causal asso-
ciation with a wide variety of brain malformations and optic nerve hypoplasia 
with maternal diabetes and toxic intake during gestation such as alcohol and 
drugs (LSD, cocaine, quinine…). Very rarely, missense mutations occur in the 
PAX6 gene and are responsible for optic nerve hypoplasia through abnormal 
development of ganglion cells and their axons. Optic disc coloboma and optic 
nerve hypoplasia have been also reported in two Indian patients sharing mis-
sense mutation in PAX6 gene.98 (See Figure 14 and 15) 
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Figure 14. Optic Nerve Coloboma (From Dutton NG. Eye 2004). 
 
 
 
Figure 15. Optic Nerve Hypoplasia (From Taylor et al. Eye 2007). 
Morning Glory Disc anomaly 
This affection bears its name because of similarities with the flower of the same 
name. There is a central glial tuft, retinal vessels that exit in a radial fashion 
from the enlarged posterior scleral opening where the optic nerve tissue exits 
the globe, and a variable degree of peripapillary pigmentation. The origin of the 
disease results from poor development of the lamina cribosa and the posterior 
sclera. It is associated with several ocular and neurological diseases. Once 
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again, there has been one report implying missense PAX6 mutation among 
patients disclosing morning glory disc anomaly.100 (See Figure 16) 
 
 
 
Figure 16. Morning Glory Disc Anomaly (From Taylor et al, Eye 2007). 
PAX6 gene and evolution 
Despite important differences between insects and vertebrates in their eye 
structure and eye formation, genetic studies have shown that eyes from very 
different species might share a similar developmental cascade of transcriptor 
factors. Indeed, PAX6 gene sequence and its expression pattern are both re-
markably similar among very different species of animals. For example, Eye-
less, the PAX6 homolog of Drosophila shows extensive sequence similarity with 
human PAX6, both in the paired domain (94% identity), and in the homeodo-
main (90% identity).101 The zebrafish pax(zf-a) protein exhibits 96% of homol-
ogy of the amino acid sequences with human PAX6.102 Closer to us the mice 
and human PAX6 proteins are identical in amino acid sequence.49 To our 
knowledge, homology of PAX6 gene has been found among several different 
species including: Saccoglossus kowalevskii, Florida lancelet Ciona intestinalis, 
Drosophila melanogaster, mosquito, zebrafish, Japanese rice fish, Xenopus 
laevi, chicken , mouse, rat, rabbit, cow, dog, gray short-tailed opossum, sheep, 
rhesus monkeys, chimpanzee (Seen in PubMed, Homologene PAX6). The de-
gree of homology is particularly higher in the paired domain and the homeodo-
main, which both interact with DNA to exert their controls on a cascade of 
genes implied in eye formation and regulation. 
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Such a high degree of conservation among species is very rare and comparable 
to the one found with histones H2A and H2B.103 
Pax6 in the mouse 
The small eye gene (Sey) gene that is located on chromosome 2 of the mouse 
has been assumed to be the homolog of human PAX6 gene or Aniridia gene.104 
Homozygous Pax6, Sey, null mutation in the mouse is lethal shortly after birth 
and associated with absence of eyes, nasal structures and pancreas, with se-
vere brain defects and sometimes abnormal dentition.47,105 
Heterozygous Pax6 +/- mice produce low levels of PAX6 and result in ocu-
lar abnormalities secondary to abnormal eye development (detailed below) and 
abnormalities in forebrain development,39 olfactory bulb30 and the pancreas.106 
Pax6 +/- heterozygous mice disclosed several ocular phenotypes that range 
from microphthalmia, aniridia-like iris anomalies,107 corneal opacities, lens-
corneal adhesions that resemble Peters’ anomaly108,109 to trabecular meshwork 
development abnormalities.110 Other developmental abnormalities, including 
retinal dysplasia, coloboma, abnormal cell accumulation in the vitreous, iri-
docorneal synechia and adhesions between the lens and cornea may also oc-
cur.110-115 Pax6 +/- adult mice present a very thin and fragile corneal epithelium 
and a vascularised stroma that is infiltrated by inflammatory cells. These mice 
show a progressive corneal deterioration and abnormal wound healing charac-
terized by increased stroma cell apoptosis and reduced level of MMP9 (Matrix 
metallopeptidase 9).114,116 
Overexpresion of Pax6 gene 
Not only low levels of Pax6 during eye development are resulting in severe ocu-
lar phenotypes. It has been also demonstrated that experimentally induced 
overexpression of Pax6 in the mouse and duplication of PAX6 gene in the hu-
man cause eye abnormalities as well. Therefore development seems to be very 
sensitive to correct Pax6 gene dosage.117-119 
Using a transgenic approach, additional copies of the Pax6 gene have been 
introduced into the mouse genome.119 The transgenic mice carries 2 to 10 cop-
ies of the human PAX6 gene all integrated in the same locus. These mice 
strains showed variable eye abnormalities, ranging from an almost normal ex-
ternal appearance to severe microphthalmia depending on the number of hu-
I n t r o d u c t i o n  
 29 
man PAX6 copies and genetic background of the rescued mice. Pax6 overex-
presion resulted in microcornea, iris hypoplasia, disorganized iris and ciliary 
body, moderate to severe cataract, complete absence of photoreceptor layer, 
retinal dysplasia and dysgenesis, defects in RGC axon growth and guidance 
and microphthalmia.118-120 
In humans, PAX6 duplication or partial duplication was encountered in a few 
patients with chromosome abnormalities. One girl had a duplication of chromo-
some band 11p12-->13, which includes the Wilms tumor gene (WT1) and the 
aniridia gene (PAX6). She showed developmental delay, mild facial anomalies, 
and eye abnormalities consisting in abnormal eye movements, hypermetropia, 
nystagmus, and slight abnormal fundus such as pale optic disc with peripheral 
patch of atrophy.117 Partial duplication of PAX6 was seen among patients with 
complete or partial trisomy of 11p, including 11p13. Those patients share in 
common mental retardation, growth retardation, hypertelorism, flat or broad 
nasal bridge, cleft lip or palate and ophthalmic anomalies. 
Ophthalmological findings in these patients were variable and comprised 
abnormal visual acuity, abnormal eye movement, microphthalmia, and abnor-
malities of the conjunctiva, choroid, retina, and the macula.121-128 
Pax6 over-expression: Ectopic expression of Pax6 
A very interesting way of testing a gene function is to study its over-expression 
or its ectopic expression, meaning testing its expression in an unusual location. 
In the Drosophila, Eyeless gene, a homolog of human PAX6 gene, was tested 
for these experiments. The yeast transcription factor gal4 drive Eyeless cDNA 
into imaginal discs other than the eye disc and is expressed not only in the de-
veloping eye, but also everywhere in the body, this results in the apparition of 
ectopic eyes on the antennae, wings, thorax of the Drosophila.36 Electroretino-
grams performed on of the ectopic eyes of the antennae showed that they were 
fully functional.129 (See Figure 17) 
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Figure 17. Ectopic Eyes on Drosophila (From Hadler et al. Science 1995). 
Similarly, experiments performed first on the Xenopus laevis were able to in-
duce ectopic lens.37 Later, in Xenopus laevis, a similar experiment led to ectopic 
eye apparition35 after Pax6 RNA injections in embryos of Xenopus laevis. These 
experiments also revealed that activity of misexpressed Pax6 causes the ec-
topic expression of a number of genes including Rx, Otx2, Six3 and endoge-
nous Pax6, each of which has been implicated in eye development. 
The most remarkable finding in these reports was that the ectopic expres-
sion of the mouse Pax6 gene within the fly (Drosophila) resulted in a phenotype 
very similar to the fly gene ectopic expression. These eyes were, Drosophila 
eyes and not mouse eyes, because only the main switch to trigger eye devel-
opment was changed (Pax6 mouse gene) and all of the other genes required 
for forming an eye (estimated to be ~ 2,000) were provided by the Drosophila 
host.36 Reciprocally, experiments in which the Drosophila Pax6 homolog, Eye-
less and Twin of Eyeless, were expressed in Xenopus embryos, resulted in the 
formation of vertebrate eye structures.130 
All these observations suggested that at least some of the functions of Pax6 
in eye development were conserved from invertebrates to vertebrates. 
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Anatomy of the retina 
The retina is approximately 0.5 mm thick and lines the back of the eye. The 
optic nerve contains the ganglion cell axons running to the brain and, addition-
ally, incoming blood vessels that open into the retina to vascularise the retinal 
layers and neurons (See figure below). A radial section of the retina reveals that 
the ganglion cells lie innermost in the retina closest to the lens and the photore-
ceptors (the rods and cones) lie outermost in the retina against the pigment 
epithelium and choroid. Light must, therefore, travel through the thickness of the 
retina before striking and activating the rods and cones. Subsequently the ab-
sorption of photons by the visual pigment of the photoreceptors is translated 
into first a biochemical message and then an electrical message that can stimu-
late all the succeeding neurons of the retina. The retinal message concerning 
the photic input and some preliminary organization of the visual image into sev-
eral forms of sensation are transmitted to the brain from the spiking discharge 
pattern of the ganglion cells.131 (Figure 18) 
 
 
Figure 18. Anatomy of the retina (From Helga Kolb et al. Webvision 2007). 
 
The retina is composed of three layers of nerve cell bodies and two layers of 
synapses. The outer nuclear layer contains cell bodies of the rods and cones, 
the inner nuclear layer contains cell bodies of the bipolar, horizontal and 
amacrine cells and the ganglion cell layer contains cell bodies of ganglion cells 
and displaced amacrine cells.132 
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The central retina is cone-dominated retina whereas peripheral retina is rod-
dominated. The outer nuclear layer (ONL) is composed of the cell bodies of the 
rods and cones and discloses the same thickness in central and peripheral ret-
ina. However in the peripheral the rod cell bodies outnumber the cone cell bod-
ies while the reverse is true for central retina. In central retina, the cones have 
oblique axons displacing their cell bodies from their synaptic pedicles in the 
outer plexiform layer (OPL). These oblique axons with accompanying Muller cell 
processes form a pale-staining fibrous-looking area known as the Henle fiber 
layer. The latter layer is absent in peripheral retina.133-135 
The inner nuclear layer (INL) is thicker in the central area of the retina com-
pared with peripheral retina, due to a greater density of cone-connecting sec-
ond-order neurons (cone bipolar cells) and smaller-field and more closely-
spaced horizontal cells and amacrine cells concerned with the cone path-
ways.136 A remarkable difference between central and peripheral retina can be 
seen in the relative thicknesses of the inner plexiform layers (IPL), ganglion cell 
layers (GCL) and nerve fiber layer (NFL). This is again due to the greater num-
bers and increased packing-density of ganglion cells needed for the cone path-
ways in the cone-dominant foveal retina as compared the rod-dominant periph-
eral retina. The greater number of ganglion cells means more synaptic interac-
tion in a thicker IPL and greater numbers of ganglion cell axons coursing to the 
optic nerve in the nerve fiber layer. 
OLM (outer limiting membrane), ONL (outer nuclear layer), OPL (outer 
plexiform layer), INL (inner nuclear layer), IPL (inner plexiform layer), GCL 
(ganglion cell layer), ILM (inner limiting membrane). 
Muller cells are the radial glial cells of the retina. The outer limiting mem-
brane (OLM) of the retina is formed from adherent junctions between Muller 
cells and photoreceptor cell inner segments. The inner limiting membrane (ILM) 
of the retina is likewise composed of laterally contacting Muller cell end feet and 
associated basement membrane constituents. (See Figure 19) 
The OLM forms a barrier between the subretinal space, into which the inner 
and outer segments of the photoreceptors project to be in close association with 
the pigment epithelial layer behind the retina, and the neural retina proper. The 
ILM is the inner surface of the retina bordering the vitreous humor and thereby 
forming a diffusion barrier between neural retina and vitreous humor. 
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Figure 19. Histology of the Retina (From Helga Kolb et al. Webvision 2007). 
Age Related Macular Degeneration and Retinitis Pigmentosa 
Age related macular degeneration (AMD) is the leading cause of blindness 
among elderly people in western countries. It is a multifactorial disease.137-140 
The disease affects 10 millions patients in the USA. AMD can present under a 
“dry” or a “wet” form. (Figure 20) 
 
 
Figure 20. Wet AMD (From private collection, Stanescu-Segall). 
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Wet AMD, or exudative AMD, is composed of choroid new vessels (CNV) cross-
ing the retinal pigment epithelial barrier and invading the retina. These new 
vessels, lack tight junction, and allow leakage of fluid (serum, lipids, proteins) 
and blood inside the retina. VEGF (Vascular Endothelial Growth Factor) has 
been implicated in the formation of CNV and therapies involving anti-VEGF are 
now used in current practice with promising results.141-144 Dry AMD results in 
progressive loss of the photoreceptors cells and RPE of the macular region. Up 
to date, there is no proven treatment for dry AMD. Injections of growth factor 
have been advocated to slow the progression of the disease, but further studies 
are warranted to confirm their efficacy.145 Retinitis Pigmentosa (RP) is among 
the leading cause of decrease vision among young patients.146 The prevalence 
of RP is reported to be approximately 1 in 4000 in the United States. RP is a 
group of inherited disorders characterized by initial progressive peripheral vision 
loss and night vision difficulties that can lead secondary to central vision loss.147 
Up to date, there is no cure for RP. Different treatment modalities such as gene 
therapy,148,149 growth factor injections,150-152 stem cell,153,154 retina transplanta-
tion155,156 and retina prosthesis157 are currently under investigation158 and offer a 
chance of hope for RP patients in the future. Several studies on the pathophysi-
ology of dry AMD and RP have shown that both diseases loose their photore-
ceptor cells by apoptosis.159-163 Therefore, understanding the process of photo-
receptor apoptosis might shed some light on how to interfere with photoreceptor 
loss and subsequent loss of vision in these diseases. There is no real mouse 
model of AMD, since mice do not carry a proper macula. Although, anomalous 
reactions in the visual cycle have been shown to cause an AMD-like phenotype 
in mice lacking both the ATP-binding cassette transporter 4 (Abca4) and retinol 
deshydrogenase 8, two enzymes critical for all-trans- retinal clearance from the 
retina.164 (Figure 21) 
In case of RP, genetically engineered animal models carrying a mutation 
known to cause RP in patients has been extensively used. Indeed, the number 
of transgenic mice mimicking human inherited degenerations is constantly 
growing.165,166 We have paid particular attention in our study to Pde6b(rd1) 
mouse, one of the most studied mouse models of human retinal degeneration. 
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Figure 21. Retinitis Pigmentosa (From private collection, 
Stanescu-Segall). 
Light induced retinal degeneration 
Light exposure is responsible for photoreceptor apoptosis, consists in a non-
genetic induced mouse model of RP.160 We have used this mouse model of 
light-induced retinal degeneration in our study for all the advantages it encom-
passes. Adult mice are exposed to a bright light of an average of 10.000 lux for 
a period of two hours. This exposure leads to photoreceptor degeneration after 
24 hours and their complete physical disappearance within 10 days, much 
faster than most inherited mice model of retinal degeneration. Light exposure 
induced apoptosis in all affected photoreceptors in a synchronized way; they will 
pass through different stages of apoptosis more or less at the same time. This 
allows the detection of biochemical markers and their assignment to different 
phases of apoptosis.167 Finally, several animal models have shown an accelera-
tion of their retinal degeneration when exposed to increased light levels. There-
fore, light plays a real role as a co-factor in retinal disease. The advantage of 
that model is that a synchronized burst of cell death is created and control stud-
ies on a cellular and molecular levels are possible based on light intensities, 
spectral dependences, stain differences, protective and genetic regulations. 
On the molecular level, light-induced photoreceptor degeneration appears 
to proceed in separate phases from induction of apoptosis to clearance of the 
cellular remnants. In the induction phase, rhodopsin, a visual pigment found in 
the rod photoreceptors, plays an essential role in the apoptosis mechanism. 
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During light exposure rhodopsin is bleached, which causes release of the reti-
noid from the opsin molecule. The retinoid is transferred to the retinal pigment 
epithelium and is regenerated by multiple enzymatic steps.168 Particularly, the 
necessity of 11-cis retinal regeneration is paramount in order to obtain light 
damage and furthermore indicate that rhodopsin regeneration during light expo-
sure is a crucial determinant of damage susceptibility. A second phase, death 
signal transduction, consists in an increase in intracellular calcium levels, le-
sions of mitochondria, an increase in NO and ROS. It also comprises activation 
of the transcription factor AP-1, composed of members of the Jun family of pro-
teins. The DNA binding activity of AP-1 increases already during light exposure, 
to reach a peak 6–12 h following the exposure.169,170 Analysis of the AP-1 com-
plex composition under these conditions revealed that AP-1 consists mainly of 
c-Fos and JunD/c-Jun.169,170 Interestingly, studies have demonstrated that c-fos 
knockout mouse were resistant to light because they lack the c-fos component 
of AP-1. The last phase is the termination phase and consists of DNA degrada-
tion by internucleosomal DNA cleavage that occurs between 30 and 36 h follow-
ing light exposure. About 1 day following light exposure blebbing of photorecep-
tor nuclei becomes evident, which indicates the terminal disintegration of these 
organelles. Nuclear decay reaches its maximum between 2d and 3d following 
the insult.171 Coinciding with this phase of nuclear disintegration macrophages 
invade the retina and phagocyte photoreceptor debris.171,172 
The Pde6b(rd1) mouse 
Pde6b(rd1) mouse or retinal degeneration mouse are homozygous for the 
Pde6b(rd1) mutation and disclose the same clinical features of human retinitis 
pigmentosa. This mouse carries a nonsense mutation in exon 75 and a proviral 
insert in intron 1 of the gene encoding the Beta-subunit of cyclic guanosine mo-
nophosphate-phosphodiesterase. (PDE) leading to an elevation of retinal cGMP 
levels and rapid postnatal degeneration of the photoreceptor. 
These mutations result in a nonfunctional gene product. Recently is has 
been shown that photoreceptors die by apoptosis beginning around postnatal 
day 8 and totally disappear after one month. Pde6(rd1) mice has been exten-
sively studied and used as a mice model for Retinitis Pigmentosa and retinal 
degeneration. (See Figure 22) 
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Figure 22. Rd Mouse (From private collection, Stanescu-Segall) 
Glaucoma 
Glaucoma is the second most common cause of blindness in developed coun-
tries. Primary glaucoma affects approximately 70 millions people worldwide, half 
of them with angle-closure glaucoma (ACG).173,174 It is a multifactorial disease 
and consists primarily in raised intraocular pressure. The raised intraocular 
pressure causes damage to the optic nerve and the retina. In the retina, there is 
a loss of optic nerve fibers and retina ganglion cells. 
The prevalence of blindness in ACG is two times higher than other forms of 
glaucoma.175 ACG exists in acute, intermittent/ subacute and chronic forms,176 
and results from increased IOP (intra-ocular pressure) caused by the iris oblit-
erating the trabecular meshwork.175 This leads to reduced and blocked aqueous 
outflow and anterior peripheral synechia between the iris and cornea. ACG 
pathophysiology is largely unknown, and believed to be related to acute and 
chronic atony of the pupillary sphincter muscle. A mouse mode reproducing 
acute ACG has been genetically modified for that purpose (see below) 
Glaucoma is generally treated with different types of eye drops that de-
crease intraocular pressure or protects inner retina cells from secondary retinal 
degeneration. If drop therapy fail to reduce intraocular pressure, laser trabecu-
loplasty of filtering surgery is then offered to the patient. 
(See Figure 23) 
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Figure 23. Optic Disc in Glaucoma patient (From private
collection, Stanescu-Segall) 
Mouse model of angle-closure glaucoma: calcitonin receptor-like 
receptor transgenic CLRSMαA 
Conversely to DBA/2J transgenic mice that mimic chronic ACG,177 the CLRSMαA 
transgenic mice disclosed the same features of acute and intermittent angle-
closure glaucoma. CLRSMαA mice overexpress CLR/RAMP2 Adrenomedullin 
(AM) receptors in the pupillary sphincter muscle, resulting in enhanced AM-
induced sphincter muscle relaxation.178 Indeed, AM, is a smooth-relaxing poly-
peptide, that could be found naturally in the iris and ciliary body of the eye.179 
The sphincter muscle relaxation of these mice lead to acute elevation of 
IOP between 1 and 3 months and represent a good model of acute ACG.178 
Aim of the study 
The aim of this thesis was to investigate the function and the role of PAX6 gene 
and its protein PAX6 in both normal development and retinal degenerations of 
vertebrates and more specifically in mouse and human. 
Little is known about PAX6 and its role after the end of ocular development. 
PAX6 is known to be the master gene for eye formation during its development. 
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We have seen that both over-expression and under-expression of PAX6 gene 
results in severe ocular abnormalities. An exact dosage of the PAX6 gene is 
required and paramount for the normal development of the eye and normal 
function of the cornea in adulthood. 
Our first question was to see whether PAX6 expression and its protein were 
still present and active after the end of ocular development. In general, genes 
that are activated during the development of specific organs stop being active 
right after or shortly after the end of development of its specific organ. 
It has been shown that PAX6 protein is mainly located in the epithelial lay-
ers of the cornea, the anterior capsule of the lens and in the inner layers of the 
retina. On IHC (Immuno Histo Chemistry), PAX6 was mainly located in the inner 
layer and ganglion cell layer of the retina. 
Retinal degenerations such as AMD (age-related macular degeneration) 
and RP (Retinitis Pigmentosa) have been in the centre of attention of research 
in the last twenty years. Pde6b(rd1) mouse was the first and most well-known 
mouse model of genetically induced retinal degeneration. Light-induced retinal 
degeneration results from exposing mice to 12.000 Lux for two hours. These 
mice demonstrated a fast and reproducible degeneration of their retina within 24 
hours. Both mouse models have been extensively studied in retinal degenera-
tion. Therefore, we were wondering whether Pax6 expression would be modi-
fied in those two mouse models of retinal degeneration. Both IHC and WB 
(Western Blot) techniques were used to asses Pax6 expression in the retina of 
wild type mice, Pde6b(rd1) mice, light induced retinal-degeneration mice and c-
fos knockout mice that showed resistance to light-induced retinal degeneration. 
All the experiments were performed on adult mice of the same age. 
Because, PAX6 was mainly located in the inner layers of the retina, we were 
also interested to study its expression in diseases affecting more predominantly 
the ganglion cell layer of the retina. 
CLRSMαA mouse is a genetically modified mouse that shares the same char-
acteristics of angle closure glaucoma. In these mice, ocular hypertension result-
ing from blockage of outflow, leads to RGC cell death. We studied Pax6 ex-
pression in this mouse model. 
Finally, it was also interesting while studying, retinal degeneration and more 
particularly; light induced retinal degeneration to look at different mechanisms 
that might protect the apoptosis of the outer retina cell layers. Epo, surprisingly 
appeared to be an essential factor in protecting the retina of mice exposed to 
light induced retinal degeneration. 
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Abstract 
Purpose: PAX6 is the master gene for ocular development in a variety of spe-
cies. In mice, it is continuously expressed throughout development and adult-
hood.Although, little is known of its role after completion of ocular development. 
Methods: We investigated the pattern of Pax6 expression in adult mice models 
for inherited (Pde6b (rd1)) and light-induced retinal degeneration, and in c-fos-/- 
mice exposed to light by immunohistochemistry and western blot techniques. 
Results: We have shown that PAX6 was predominantly localized in the gan-
glion cell layer and inner nuclear layer of both the degenerating and non-
degenerating retina. Pax6 was expressed in the retina throughout the lifespan 
of the adult mouse. In Pde6b (rd1) retinas, we observed a distinct reduction in 
PAX6 protein levels between days 10 and 14 during the peak of photoreceptor 
apoptosis. Similarly, wild-type mice showed decreased Pax6 expression during 
light-induced photoreceptor apoptosis. C-fos-/- mice protected from light-induced 
damage, however, disclosed an increase of Pax6 expression after exposure to 
bright light. 
Conclusion: The observed reduction of PAX6 levels during inherited and in-
duced retinal degeneration and its increase in protected c-fos-/- mice is sugges-
tive of a potential protective role in retinal degeneration. 
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Introduction 
PAX6, a member of the paired box family of transcription factors, is an essential 
gene for ocular morphogenesis both in vertebrates and invertebrates.1 PAX6 is 
highly conserved throughout evolution: the murine and human PAX6 proteins 
are identical in their amino acid sequence and Ey (Eyeless), the Drosophila 
homolog of PAX6, shows over 90% homology with both the paired and the 
homedomain of the mouse small eye gene.2 Various PAX6 mutations have 
been identified leading to a large variety of ocular abnormalities and diseases in 
mice and humans with striking similarities between the species.1,3–6 
Although PAX6 has been extensively studied in eye development in a vari-
ety of species, little is known about the role of PAX6 in the adult and ageing 
mammalian retina. De Melo and co-workers have studied Pax6 expression in 
the developing and young adult mouse retina and Birke and al have shown a 
continuous expression of Pax6 throughout the lifespan of a mouse (submitted).7 
We analyzed the expression of Pax6 in mice models of retinal degeneration 
consisting of inherited (Pde6b(rd1)) mice and light-induced retinal degeneration 
for both c-fos and c-fos knockout mice. 
The Pde6b(rd1) mouse is a common model for inherited retinal degenera-
tion.8,9 It carries a proviral insert in the gene encoding for the beta-subunit of 
cyclic guanosine monophosphate-phospodiesterase (beta-PDE) and shows 
progressive outer retinal degeneration through photoreceptor degeneration 
starting at p9 with completion at p21.8,10 
C-Fos knockout mice have shown resistance to light-induced retinal degen-
eration (11). C-fos plays an essential role in light-induced apoptosis of photore-
ceptors: after exposure to bright white light, wild-type mice (c-fos+/+ mice) dis-
play severe loss of photoreceptor cells due to apoptosis, whereas retinas of 
mice without c-Fos (c-fos-/- mice) remain unaffected. The observed resistance to 
light-induced apoptosis in c-fos-/- mice may indicate an active contribution of c-
Fos and its role on the regulation of rod-specific gene expression to the apop-
totic cascade triggered by light.11 
In the current study, we have studied Pax6 expression by immunohisto-
chemistry (IHC) and by western blot in adult mice in different animal models of 
retinal degeneration: the Pde6b(rd1) mouse, a model for autosomal recessive 
human Retinitis Pigmentosa, in light-induced retinal degeneration in wild-type 
mice and in c-fos-/- mice.11–14 
 
P a x 6  e x p r e s s i o n  i n  t h e  m o u s e  r e t i n a …  
 52 
Materials and methods 
Animals 
All animals’ experiments were conducted in accordance with the regulations of 
the University of Zurich, and adhered to the statement of the Association for 
Research in Vision and Ophthalmology for the use of animals in ophthalmic and 
vision research. Wild-type mice (C3H background) were obtained from Wiga 
(Sulzfeld, Germany). 
C-fos knockout (c-fos-/-, C3H background, The Jackson Laboratories, 
Maine) and Pde6b (rd1) mice (C3H background) and their corresponding wild-
type controls were identified by PCR analysis of genomic DNA isolated from 
mouse tails as described elsewhere.15,16 Mice were maintained in a 12:12 light-
dark cycle (lights on at 6 am). For experiments, 3 animals of each genetic back-
ground were sacrificed at different postnatal days. All animals were sacrificed at 
the same time of the day (2 pm) to avoid diurnal variations. 
Tissue preparation 
Animals were killed by cervical dislocation under CO2 asphyxiation. Eyes were 
rapidly enucleated and fixed in 2% paraformaldehyde for 2 hours followed by 
dehydration and paraffin embedding for histochemical analysis; or they were 
fixed in 2.5% glutaraldehyde for 12 hours, dehydrated and processed for light-
microscopic analysis. For western blot analysis, retinas were rapidly removed 
through a slit in the cornea, immediately frozen in liquid nitrogen, and stored at 
−80 °C. Cellular homogenates were prepared from shock-frozen whole retinas 
by sonification in 100 μM TBS. Protein concentrations were determined using 
the Bradford protein assay (Bio-Rad, Hercules, USA) or the BCA assay (Pierce, 
Rockford, USA) with BSA as standard. 
Light damage 
Before light exposure, animals were dark-adapted for 16 hours overnight. Pupils 
were dilated under dim red light with 1% Cyclogyl (Alcon, Cham, Switzerland) 
and 5% phenylephrine (Ciba Vision, Niederwangen, Switzerland), followed by 
exposure to diffuse white fluorescent light with an luminance of 15000 lux for 30 
minutes in cages with a reflective interior. After light exposure, animals were 
analyzed immediately or following a period in darkness.  
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Immunohistochemistry 
Eight µm sections were deparaffinized in xylene and dehydrated in ascending 
ethanol series (0, 25, 50, 75 and 100%). To enhance immunoreactivity, sections 
were incubated in 10 mM citrate buffer (pH 6.0) and boiled in a steamer at 
100°C for 5 minutes. Endogenous peroxidase activity was eliminated by incuba-
tion in 3% hydrogen peroxide in distilled water for 15 min. After incubation with 
the affinity-purified rabbit polyclonal mouse PAX6 antibody at 4°C, a biotinylated 
secondary anti-rabbit antibody was applied, followed by the avidin-biotin-
peroxidase complex (Dako, Carpinteria, Ca, USA).17 Sections were stained 
using 3,3’-diaminobenzidine. The absence of the primary antibody was used as 
a negative control. 
Western blot analysis 
Total retinal protein extracts were separated by SDS-PAGE (7.5%) and western 
blot analysis was performed according to standard protocols. For immunodetec-
tion, a polyclonal rabbit antiserum directed against PAX6 (Covance Research 
Products, Berkeley, CA, USA) was applied to 5µg total retinal protein. Horserad-
ish peroxidase (HRP)-conjugated secondary antibody (Santa Cruz Biotechnol-
ogy, CA, USA) was applied, and immunoreactivity visualized using a kit (Ren-
aissance Western Blot Detection; Dupont NEN Life Science Products, Inc., Bos-
ton, MA). Mouse monoclonal anti-β actin was used from Abcam (Cambridge, 
MA). The retinas of three animals were used for each time-point. Protein bands 
of actin and Pax6 were analyzed with gel image analysis software (Image J 
Software). 
Results 
Specificity of the antibody 
The specificity of the antibody was examined by western blot analysis. Blots 
display a band with a molecular weight of 46 kDa, some blots showing a second 
band of 48 kDa corresponding to the splice variant of PAX6 RNA, PAX6 (5a).23 
As an internal control, labeling with an antibody against actin was performed. 
Actin levels remained constant throughout all time points tested in all experi-
ments performed. (Data not shown) 
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Time course of Pax6 expression in Pde6b (rd1) mice and in wild type mice 
Figure 1 shows Pax6 expression in wild type mice at p6, 8, 10, 14, 16, 21 28 
and 243 by western blot and IHC of PAX6 in the retina at p14. There is a pro-
gressive decrease of Pax6 expression with time. Beta-actin was used as a con-
trol. IHC showed that PAX6 was expressed in both the INL and the GCL in the 
same manner at all time-points. Figure 2a and b show progressive degeneration 
in the outer retina in Pde6b (rd1) mice at p8 and p21 with deteriorated Rod In-
ner Segments (RIS) and scattered condensed photoreceptor nuclei. IHC was 
performed at p 6, 8, 10, 14, 16, 21 and 28 (Fig. 2c and d show p8 and p21, re-
spectively). At all time points tested, expression was confined mainly to both the 
INL and the GCL. In both layers, labelling was predominantly found in the nu-
clei. Furthermore, in the INL, labelling occurred primarily in the inner part 
whereas the outer part remained negative. Pax6 expression and localization 
remained unchanged at the different time-points in immunohistochemistry. 
Western blot analysis of Pax6 expression showed a distinct decrease at p10 
and p14, followed by an increase to previous levels in Pde6b(rd1) mouse. Actin 
expression levels were comparable at all time points tested (Fig. 2e). 
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Figure 1. Pax6 expression in adult wild-type (C3H) mice throughout adulthood. 
(A) Photomicrograph of retinal section from wild-type mouse. (B) Immunohistochemical analysis 
shows PAX6 expression confined to the nuclei of the INL and GC. (C) Western blot analysis of
PAX6 showed its expression since postnatal day 1untill postnatal day 428. There is a decrease 
of expression during the first four weeks. After, expression of PAX6 remains stable until p428. 
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Figure 2. Pax6 expression in Pde6b(rd1) mice. 
(A, B) Light micrographs of retinal sections at p8 and p21. Pde6b mice show deteriorated RIS and 
scattered condensed photoreceptor nuclei in the ONL. The inner retina shows normal morphology. 
(C, D) Immunohistochemical analysis shows PAX6 expression confined to the nuclei of the INL
and GCL at p8 and p21 (arrows). (E) Western blot analysis of PAX6 expression in Pde6b mice 
shows a distinct decrease of PAX6 levels at p10 and p14. As loading controls, each immunoblot 
was probed with anti-actin antibody. Bar analysis of ratio of Pax6 over actin expression in
Pde6b(rd1) mouse. 
Rod Inner Segments (RIS); Outer Nuclear Layer (ONL); Inner Nuclear Layer (INL); Ganglion Cell
Layer (GCL). 
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Pax6 expression after light-induced retinal degeneration in wild-type and c-fos-/- 
mice 
Wild-type (Fig. 3a) and c-fos-/- (Fig. 3c) mice showed regular retinal morphology 
before light exposure. At 6h after light exposure, distinct signs of apoptosis in 
the outer retina were observed in wild-type mice (Fig. 3b) whereas the retinas of 
c-fos deficient mice remained unchanged (Fig. 3d). 
PAX6 protein expression showed a decrease in wild-type mice immediately 
after induction of light damage and 2 hours after 15.000lux illumination and 
returned to initial values after 6 hours of light induced retinal degeneration. In C-
fos deficient mice Pax6 expression increased immediately after illumination and 
kept increasing 2 and 6 hours after light exposure. Actin levels remained con-
stant throughout all time points tested in both type of mice. (Fig 3e) 
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Figure 3. Pax6 expression ‘in light-induced retinal degeneration. 
(A,B,C,D) Photomicrographs of retinal sections from dark adapted animals and 6 hours after light-
induced retinal degeneration. Dark-adapted retinas of wild-type mice (A) and c-fos deficient mice (C) 
show regular retinal structure. At 6 hours after light exposure, the outer retina of wild-type mice 
shows substantial degeneration with disrupted ROS, condensed RIS (arrowhead) and apoptotic 
nuclei in the ONL (arrow) (B), whereas c-fos deficient mice do not show damage (D). The layers of 
the inner retina are preserved in both genotypes. (E) Western blot analysis of Pax6 expression in 
light-induced retinal degeneration in dark, and after light exposure. Wild-type mice show a reduction 
of Pax6 expression during illumination with 15’000 lux (15klux) and 2 hours after illumination (+2h) 
and return to dark-adapted levels at 6 hour after exposure to light. C-fos knockout mice disclose an 
increase in PAX6 protein levels during illumination and up to 6 hours after exposure to light. Beta-
actin western blot used as control are showed below. As loading controls, each immunoblot was 
probed with anti-actin antibody.Bar analysis of ratio of Pax6 over actin expression in light-induced 
and c-fos knockout mouse. 
Rod Outer Segments (ROS); Rod Inner Segments (RIS); Outer Nuclear Layer (ONL); Inner Nuclear 
Layer (INL); Ganglion Cell Layer (GCL). 
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Discussion 
The predominant role of PAX6 during eye organogenesis is best demonstrated 
by the analysis of the currently known mutational defects. In humans, homozy-
gous PAX6 null mutations lead to anophthalmia, brain malformation and early 
post-natal death whereas heterozygous PAX6 mutations are responsible for a 
variety of congenital abnormalities of the anterior and the posterior segment of 
the eye including autosomal dominant keratitis, congenital cataract, Peter’s 
anomaly, aniridia, optic nerve abnormalities and isolated foveal hypoplasia.18–25 
In mice, homozygous murine small eye mutations lead to a distinct phenotype 
similar to that seen in human Pax6 null mutations: early postnatal death and 
absence of eyes whereas Small eye +/- mice show the small eye phenotype 
consisting in microphthalmia, corneal and lenticular abnormalities.26,27 Similarly, 
overexpression of Pax6 results in ophthalmic abnormalities: mice carrying mul-
tiple copies of Pax6 on a wild-type background show specific developmental 
abnormalities of the eye consisting in microphthalmia, corneal abnormalities, 
cataract, a disorganized ciliary body and absence of photoreceptor layer of the 
retina.28 
Although PAX6 expression has been extensively studied during eye or-
ganogenesis in various species, relatively little is known about its expression 
after the end of ocular development. Recently, several studies have suggested 
a role for PAX6 in the maintenance of different ocular tissues. In humans, 
Stanescu et al. showed that PAX6 was continuously expressed in the ageing 
inner retina suggesting a role for PAX6 in the maintenance of the human ret-
ina.29 Zhang et al. reported the presence of Pax6 transcripts and its protein in 
adult lens epithelium and suggested a function for PAX6 in the growth and 
maintenance of the adult human lens.30 
Ouyang et al showed that corneal epithelial cell lines that overexpressed 
PAX6 had reduced cell proliferation, confirming the notion that PAX6 plays a 
role in controlling corneal epithelial cell dynamics in vivo.31 
Li and co-workers investigated heterozygous small eye mice, and demon-
strated compromised cellular adhesion of the corneal epithelium suggesting a 
role for Pax6 in the proper generation and maintenance of the adult cornea. In 
humans, Li et al. found that corneal pannus tissues from patients with different 
ocular surface diseases had a decline or absence of Pax6 expression, whereas 
normal ocular surface epithelial cells showed regular Pax6 expression. These 
results indicate that Pax6 may help maintain the normal corneal epithelial phe-
notype postnatally, and that its down-regulation was associated with abnormal 
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epidermal differentiation in severe ocular surface diseases.32 Taken together, 
these findings suggest that variation of Pax6 expression is associated with de-
generative changes in various ocular structures. To confirm this hypothesis, we 
investigated the levels of Pax6 expression in inherited (Pde6b(rd1)) and light-
induced retinal degeneration. 
The Pde6b(rd1) mouse, a common model for inherited retinal degeneration 
carries a proviral insert in the gene encoding for the beta-subunit of cyclic 
guanosine monophosphate-phospodiesterase (beta-PDE) and shows progres-
sive outer retinal degeneration through photoreceptor degeneration starting at 
p9 with completion at p21.8–10 
In Pde6b(rd1) mice, we observed a distinct decrease of Pax6 expression 
during the peak of photoreceptor apoptosis between p10 and p14 (Fig. 2e) . 
IHC, Pax6 expression was confined to the INL and GCL at all time-points 
tested. This is in contrast with the findings of Jones et al who observed an in-
crease level of Pax6 mRNA at P16.33 They considered p16 as the peak of apop-
tosis and assumed that the modulation of Pax6 mRNA levels was suggestive of 
an activation of expression of retinal glial cells. According to Farber et al, P16 is 
the peak of cyclic GMP release and not the peak of apoptosis. Therefore the 
increase in Pax6 levels is not likely to be due to a defense mechanism occurring 
in response to apoptosis. Jones investigated Pax6 mRNA, whereas we investi-
gated Pax6 protein expression. Splicing variation of Pax6 mRNA may partly 
explain the differences in results.33 
Exposure to high levels of fluorescent white light represents a model for 
light-induced retinal degeneration, a process critically depending on the activa-
tion of the transcription factor AP-1 (c-fos/junD).34 Whereas wild-type mice show 
extensive apoptosis in the outer retina upon light exposure, c-fos deficient mice 
are protected against retinal light damage. 
In accordance with our findings in Pde6b(rd1) mice, wild-type animals un-
dergoing photoreceptor apoptosis showed a decline in PAX6 levels during de-
generation whereas PAX6 levels in protected c-fos null mice (Fig. 2) showed 
increasing levels at 2 and 6 hours after illumination. The decrease of Pax6 ex-
pression at the peak of apoptosis in Pde6b(rd1) mouse and its increase in the c-
fos-/- mice resistant to light induce retinal degeneration suggests a role for Pax6 
in the maintenance of retinal cytoarchitecture 
In conclusion, we show that downregulation of Pax6 is concomitant with in-
herited and induced retinal degeneration whereas animal models protected 
against induced retinal degeneration demonstrate an increase of Pax6 levels. 
One might speculate that the level of Pax6 expression might be a co-factor that 
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should be taken into consideration in the chain of events leading to degenera-
tive retinal disease. 
Nevertheless, further studies investigating the intercellular pathways be-
tween dying photoreceptor and inner retina cells are required to increase our 
understanding of the putative protective role of Pax6 in the retina. 
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Abstract 
Background: PAX6 is a highly conserved protein essential for the control of 
eye development both in invertebrates and vertebrates. PAX6 expression per-
sists in the adult inner retina, but little is known about its functions after comple-
tion of retinal differentiation. Therefore, we investigated PAX6 expression in 
wild-type and calcitonin receptor-like receptor transgenic (CLRSMαA) mice with 
angle-closure glaucoma. 
Methods: Intraocular pressure was measured by indentation tonometry in 
anesthetized mice. Eyes of mice of both genotypes were enucleated at various 
ages and retinas were processed for morphological analysis and PAX6 immu-
nostaining. The content of PAX6 in retinal extracts was estimated by Western 
blot analysis. Retinal expression of glaucoma-related genes was analysed by 
RT-PCR. 
Results: Control mice showed normal retinal morphology between p22 and 
p428 with steady PAX6 expression in the ganglion cell layer (GCL) and the 
inner nuclear layer (INL). CLRSMαA mice examined between p22 and p82 exhib-
ited increased IOP and a progressive decrease in cell number including PAX6 
expressing cells in the GCL. The INL was not affected up to p42. Later, a sig-
nificant increase of PAX6 expressing cells concomitant with an overall loss of 
cells was observed in the INL of CLRSMαA as compared to control mice. Retinal 
upregulation of glaucoma-related genes was furthermore observed. 
Conclusions: Distinctive changes of Pax6 expression in the inner retina of 
CLRSMαA mice suggest a role in regulatory mechanisms involved in glaucoma-
related retinal cell death. The selective increase of PAX6 expression in cells of 
the INL in the degenerating INL of CLRSMαA mice may represent an attempt to 
preserve retinal cytoarchitecture. 
 
Keywords: PAX6 • Human • Angle-closure • Glaucoma • Retinal degeneration • 
Ganglion cells 
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Introduction 
PAX6, a member of the paired box family of transcription factors, is an essential 
control gene for eye morphogenesis both in invertebrates and vertebrates.1–3 Its 
importance for eye development was demonstrated in several species. The 
human and murine (Small eye) PAX6 protein are identical in their amino acid 
sequence, and the Drosophila homolog (Eyeless) shows over 90% identity over 
the paired and the homeodomain.4 Moreover, gain-of-function studies demon-
strated that targeted expression of Drosophila and PAX6 induces ectopic eyes 
in Drosophila.5 
Mutations in PAX6 lead to a variety of eye abnormalities in mice6-9 and hu-
mans10-18 including hereditary foveal hypoplasia, optic nerve malformation and 
aniridia. 
PAX6 has been studied extensively in eye and retinal development. Normal 
development of the inner retina is directly influenced by a well-elaborated spa-
tial and temporal pattern of PAX6-expression.1,6-9,19-21 However, little is known 
about PAX6 expression and function in the adult mammalian retina. De Melo 
showed that several homeobox genes including Pax6 are expressed in the 
young adult mouse retina22 and we recently reported continuous expression of 
PAX6 in the young, adult and old normal human retina.23 
To investigate the role of PAX6 expression in the adult eye and to assess 
whether PAX6 might also be involved in degenerative processes of the retina, 
we studied Pax6 expression in wild-type and in calcitonin receptor-like receptor 
transgenic (CLRSMαA) mice with acute angle-closure glaucoma.24 
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Materials and Methods 
All animal experiments conformed to the guidelines of the Veterinary Authorities 
of the Kanton of Zurich and to the statement of the Association for Research in 
Vision and Ophthalmology (ARVO) for the use of Animals in Ophthalmic and 
Vision Research. 
Animals 
CLRSMαA mice were generated and genotyped together with wild-type litter-
mates as reported.24 Three CLRSMαA mice and three control littermates were 
analyzed at indicated ages in individual experiments. Animals were sacrificed 
by cervical dislocation and experiments were performed in triplicates. 
Measurement of intraocular pressure 
IOP was measured by indentation tonometry in anesthetized mice as described 
previously.24 An average of 6 readings was considered as a single result; pre-
sented values are the average of 10 eyes per genotype at each time point 
(same mice at different ages). 
Retinal morphology 
Eyes were prepared as described previously.25 Briefly, mice were sacrificed and 
enucleated eyes were fixed with 2.5% glutaraldehyde in 0.1 M cacodylate 
buffer, pH 7.3, at 4°C overnight. The eyes were then washed in cacodylate 
buffer, incubated in osmium tetroxide for one hour, dehydrated in ascending 
ethanol series and embedded in Epon 812 (Sigma-Aldrich, St. Louis, MO, 
USA). Central retinal sections (0.5 µm; temporal - nasal) were stained with tolu-
idine blue (Sigma-Aldrich, St. Louis, MO, USA) and analyzed by light micros-
copy. 
Retinal morphometry 
CLRSMαA and control mice were sacrificed and the eyes were enucleated and 
fixed by immersion in 4% paraformaldehyde in phosphate buffered saline (PBS) 
overnight. The eyes were then dehydrated and embedded in paraffin according 
to standard protocols. Paraffin sections (5 µm) were deparaffinized in xylene, 
hydrated in descending ethanol series and stained with toluidine blue. The sec-
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tions were then washed with water, dehydrated in ethanol and mounted with 
DPX (Sigma-Aldrich, St. Louis, MO, USA). Morphometry in the GCL and INL of 
CLRSMαA and control littermates was performed by counting all cells in the re-
spective layers on 5 µm central sagittal sections under the microscope at 40-
fold magnification with the ImageJ software (http://rsb.info.nih.gov/ij/; version 
1.36a). Data were collected from 3 sections per eye of three CLRSMαA and three 
age-matched control littermates. 
Retinal immunohistochemistry 
Central sagittal sections were boiled at 95°C for 20 min in citrate buffer and 
incubated in blocking reagent (Vector Laboratories, Burlingame, CA, USA) at 
room temperature for 60 min. The sections were then incubated at 4°C over-
night with polyclonal rabbit antibodies to PAX6 (1:300) (Chemicon, Temecula, 
CA, USA). PAX6 immunostaining was visualized with secondary biotinylated 
antibodies to rabbit IgG (1:200) (Vector Laboratories, Burlingame, CA, USA) 
and Cy3-labelled streptavidin (1:200) (Sigma-Aldrich, St. Louis, MO, USA). 
Fluorescence was detected with a DX20 CCD camera (Kappa, Gleichen, Ger-
many) connected to a 0.45x projection lens of an Eclipse E600 Nikon micro-
scope equipped with a Plan Fluor 20x/0.5 DLL objective and a G-2A (Cy3) filter 
block. 
Western blot analysis 
Retinas were rapidly dissected through a slit in the cornea using the Winkler 
technique.26 The tissue was sonicated in 100 mM Tris/HCl, pH 7.5, containing 
complete protease inhibitor cocktail tablets (Roche Diagnostics, Rotkreuz, Swit-
zerland). Retinal extracts were cleared by centrifugation and proteins were 
separated by SDS-PAGE (12%) and then electrotransfered to nitrocellulose 
Hybond ECL membranes (GEHealthcare Europe GmbH, Otelfingen, Switzer-
land) in a Trans-Blot SD semi-dry transfer cell (Bio-Rad Laboratories, Hercules, 
CA, USA). The membranes were blocked with 5% low fat milk. PAX6 was de-
tected with corresponding polyclonal antibodies (1:5000) (Chemicon, Temecula, 
CA, USA) and alkaline phosphatase-conjugated secondary antibodies 
(1:15000) (Sigma-Aldrich, St. Louis, MO, USA). PAX6 was normalized to actin 
as a protein loading control. Actin was detected with mouse monoclonal anti-
bodies to actin (1:5000) (Sigma, Buchs, Switzerland) and alkaline phosphatase-
conjugated secondary antibodies (1:15000) (Sigma-Aldrich, St. Louis, MO, 
USA). Alkaline phosphatase activity was visualized with the Bio-Rad detection 
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kit (Bio-Rad Laboratories, Hercules, CA, USA) and a VersaDoc Imaging System 
(Bio-Rad Laboratories, Hercules, CA, USA). 
Reverse transcription and semi-quantitative PCR 
Retinas were prepared from CLRSMαA mice and control littermates as described 
above and frozen in liquid nitrogen. Total RNA was isolated with the RNeasy kit 
(QIAGEN, Hilden, Germany) and cDNA was generated with M-MLV reverse 
transcriptase (Promega, Madison, WI, USA). PCR was carried out with primers 
specific for glial fibrillary acidic protein (GFAP) (forward: 5’-
CCACCAAACTGGCTGATGTCTAC-3’, reverse: 5’-TTCTCTCCAAATCCAC-
ACGAGC-3’); TIMP-1 (forward: 5’-AGAAATCAACGAGACCACCT-3’, reverse: 
5’-GGGCTCAGAGTACGCCA-3’); Interleukin-1b (forward: 5’-GCAGGCAGTAT-
CACTCATTG-3’, reverse: 5’-CGTTGCTTGGTTCTCCTTGT-3’); Endothelin-2 
(forward: 5’- TTGTGAGTGCTCTACTGCG-3’, reverse: 5’-GGTGTTATCTCTT-
CCTCCATCT-3’); X-linked inhibitor of apoptosis (XIAP) (forward: 5’-
GGATCCTCTGATGCTGTGAGTTCTGATAGGAATTTCCC-3’, reverse: 5’-GA-
CTCGAGCTAAGTAGTTCTTACCAGACACTCCTCAAG-3´); Bcl-XL (forward: 5’-
GACTTTCTCTCCTACAAGC-3’, reverse: 5’-CGAAAGAGTTCATTCACTAC-3’); 
Bcl-2 (forward: 5’-TTGTGGCCTTCTTTGAGTTCG-3’, reverse: 5’-ATTT-
CTACTGCTTTAGTGAACC-3’) and GAPDH (forward: 5’-GGGTGGAGCC-
AAACGGGTC-3’, reverse: 5’-GGAGTTGC-TGTTGAAGTCGCA-3’) with Roche 
LightCycler reagents. PCR products were separated and quantified on agarose 
gels by densitometry. 
Statistical analysis 
Results are presented as the mean ± standard error of the mean (SEM). Differ-
ences between mean values were analyzed by analysis of variance using the 
Prism 3.0 software (GraphPad Software; Inc., San Diego, CA, USA). P<0.05 
was considered statistically significant. 
Results 
Pax6 is expressed in the inner retina throughout the lifespan of wild-type mice 
Retinal morphology and Pax6 expression was examined in wild-type mice at 
postnatal days (p) 5, 9, 15, 20, 24, 29, 243 and 428. Retinal morphology was 
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normal in all mice analyzed (Fig. 1a, representative retinal section at p29). Pax6 
expression was confined mainly to nuclei of cells in the inner part of the inner 
nuclear layer (INL) and, to a lesser extent, to the ganglion cell layer (GCL) at all 
time points tested (Fig. 1b, representative section at p29). Western Blot analysis 
showed continuous expression of PAX6 from p5 to p428 with a minimal de-
crease between p5 and p20 (Fig. 1c). 
 
Figure 1. PAX6 expression in the retina of wild-type mice. Morphological analysis at p29 shows 
normal cytoarchitecture of the outer and inner retina (Epon embedding, methylene blue staining) 
(a). Immunohistochemical PAX6 staining at p29 revealed PAX6 expression confined to the nuclei of
the inner nuclear layer (INL) and the ganglion cell layer (GCL) (arrows) (b). The rod inner segments 
(RIS) and the outer nuclear layer (ONL) are also shown. Western blot analysis of PAX6 expression 
in the retina of mice at indicated ages (c). Equal amounts of protein were loaded. 
Retinal damage in CLRSMαA mice with increased ocular pressure 
CLRSMαA mice presented normal IOP at the end of ocular development on p20 
(Fig. 2a). Subsequently, the IOP increased up to p62 to over 2-times higher 
levels than in control mice. Consequently, the number of apoptotic TUNEL 
stained cells in the GCL of CLRSMαA mice was higher than in control animals 
(not shown). Moreover, the expression of genes indicating gliosis or apoptosis 
of the glaucomatous retina was also altered in CLRSMαA mice (Table 1). On p32 
the gliosis-related GFAP and endothelin-2 gene-derived transcripts were found 
upregulated in CLRSMαA as compared to control animals. Endothelin-2, unlike 
GFAP transcripts, remained upregulated on p82. The tissue inhibitors of metal-
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loproteinase-1 (TIMP-1) encoding transcripts, similar to those for endothelin-2, 
were upregulated on p32 and p82. Consistent with ongoing apoptosis in the 
retina of CLRSMαA mice, interleukin-1b (Il-1b) transcripts were upregulated on 
p32 and p82 and XIAP transcripts and those encoding the anti-apoptotic pro-
teins Bcl-XL and Bcl-2 were lower than in control mice on p82. 
 
 
Figure 2. Increase in IOP over time in CLRSMαA mice (●) as compared to control littermates (○) (a). 
The data are the mean (± SEM) of IOP measurements in at least ten CLRSMαA and ten control mice 
per time point. Morphology of the ganglion cell layer (GCL), the inner nuclear layer (INL) and the 
outer nuclear layer (ONL) in representative 5 μm toluidine blue-stained central sagittal sections of 
the retina of CLRSMαA and control (wild-type) mice at indicated ages (b). Morphometric analysis of 
the GCL and the INL in control (open bars) and CLRSMαA mice (closed bars) at indicated ages (c). 
The data are the mean ± SEM of three sections per eye from three control and three CLRSMαA mice 
per time point. 
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Table 1. Relative expression levels of apoptosis-related gene transcripts determined by RT-PCR in 
retinal RNA extracts of CLRSMαA compared to control mice. 
mRNA p32 p82  
GFAP  2.95  0.78  
TIMP-1 16.85 24.53  
Il 1b  1.69  1.47  
Endothelin-2 11.45 17.98  
XIAP  0.96  0.29  
Bcl-XL  1.20  0.69  
Bcl-2  1.02  0.42  
GFAP, glial fibrillary acidic protein; TIMP-1, tissue inhibitor of metalloproteinase-1; Il1b, Interleukin-
1b; XIAP, X-linked inhibitor of apoptosis; Bcl-XL, B-cell leukemia/lymphoma extra long; Bcl-2, B-cell 
leukemia/lymphoma-2. 
 
Retinal morphology was normal in CLRSMαA mice at p22 (Fig. 2b, c). Subse-
quently, the number of cells in the GCL of CLRSMαA mice decreased more rap-
idly than in control littermates. The INL, on the other hand, showed similar and 
unchanged morphological and morphometric features in control and CLRSMαA 
mice up to p42. At p82, however, the cell number in the INL was significantly 
lower (P<0.05) in CLRSMαA than in control mice. 
Pax6 expression in the retina of CLRSMαA mice 
Pax6 expression in the retina of CLRSMαA mice and control littermates was con-
fined to the nuclei of the INL and GCL (Fig. 3a). In CLRSMαA mice, unlike in con-
trol littermates, the number of PAX6 expressing cells in the GCL decreased in 
parallel to the total number of cells between p22 and p82 (Fig. 2c, 3b). In the 
INL, on the other hand, the number of PAX6 expressing cells was indistinguish-
able in CLRSMαA and control mice up to p42, but, interestingly, on p82 the num-
ber of PAX6 expressing cells was significantly (P<0.05) higher in CLRSMαA than 
in control mice (Fig. 3). These morphometric and immunohistochemical results 
were consistent with transiently decreased levels of PAX6 on p42 and p52 and 
p62 and subsequently increased levels on p72, reaching a peak at p82 and 
being sustained at higher levels until p102 in total retinal extracts of CLRSMαA as 
compared to control mice, recognized on Western blots (Fig. 4). 
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Figure 3. PAX6 expression in the ganglion cell layer (GCL) and the inner nuclear layer (INL) in
control (wild-type) and CLRSMαA mice (a). Immunofluorescent staining of PAX6 (red, arrowheads) 
and DAPI-staining of cell nuclei (blue) in the GCL and the INL of central retinal sections also includ-
ing the outer nuclear layer (ONL) on p82. (b). Morphometric analysis of Pax6 expression over time 
in the GCL and the INL from control (open bars) and CLRSMαA (closed bars) mice. Data are the 
mean ± SEM of three sections per eye from three control and three CLRSMαA mice per time point. 
*P<0.05 compared to control mice of the same age. 
 
 
Figure 4. PAX6 expression over time was examined by Western blot analysis in retinal extracts of 
control (wild-type) and CLRSMαA mice. PAX6 and actin were visualized by enhanced chemilumines-
cence with corresponding antibodies. Representative for three independent experiments (a). Rela-
tive changes of PAX6 expression normalized to actin in the retina of CLRSMαA (closed bars) com-
pared to control (open bars) mice (b). The values obtained for the extracts of control mice at individ-
ual time points were set to 100%. The data are the mean ± SEM of three independent experiments
*P<0.05 compared to control mice of the same age. Open bars refer to expression of control mice 
and closed bars refer to CLRSMαA mice. 
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Discussion 
PAX6 is a transcription factor influencing eye morphogenesis in invertebrates 
and vertebrates.2,3 Besides the striking amino acid sequence similarities of 
PAX6 in different species, conserved regulation of expression appears to be 
vital for ocular integrity.27 Although PAX6 was extensively studied during eye 
organogenesis in various species, little is known about PAX6 expression and 
function in adult eye tissues. PAX6 expression in the GCL and INL of the inner 
retina was observed in humans,23 chicken28 and mouse29 and Zhang et al. de-
tected PAX6 expression in the adult lens epithelium.30 
To further elucidate potential roles of PAX6 in the inner retina of an adult 
eye, we investigated its expression in wild-type and CLRSMαA mice, a mouse 
model of acute angle closure glaucoma (ACG). ACG is very much underesti-
mated and suspected to affect half of all glaucoma patient worldwide and ac-
counts for 91% of bilateral glaucoma blindness in China31. ACG pathophysiol-
ogy is largely unknown and CLRSMαA mouse model appears as a reliable mouse 
model for this disease. It offers the advantage to mimic human condition with 
transient IOP peaks between one and three months24.It obviates repetitive ma-
nipulations on mouse s ’eyes and costly equipment such as lasers needed for 
laser-induced increased IOP models.32-34 It is also one of the few genetic rodent 
model that is amendable to experimental manipulation because of its shorter 
course of glaucomatous pathology. 
These mice develop angle-closure glaucoma after completion of retinal de-
velopment24 and, as shown here, suffer from progressive retinal ganglion cell 
loss. 
The retina of CLRSMαA mice expressed elevated levels of GFAP, TIMP1, in-
terleukin 1b and endothelin-2 that were also found to be upregulated in glau-
coma in previous studies. Increased GFAP is commonly observed in degenera-
tive retinal diseases35,36 whereas tissue inhibitor of metalloproteinase-1 (TIMP-
1) encoding mRNA is elevated in microglia of glaucoma patients.37 Activation of 
proinflammatory interleukin-1b might be involved in the aetiology of glau-
coma38,39 and increased endothelin-2 expression occurs in human glaucoma 
during glial activation.40 Late down-regulation of the caspase inhibitor XIAP and 
of Bcl-XL and Bcl-2 was observed in CLRSMαA mice on p82, similar to observa-
tions in degenerating retinas.41-43 Since transgenic expression of XIAP was 
shown to increase survival of cells in the inner retina in mouse models of 
ischemia44 it seems likely that the reduced expression of this inhibitor of apop-
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tosis contributes to the retinal pathology and the observed loss of neuronal 
cells. 
Our results also show a decreased Pax6 expression in the GCL of CLRSMαA 
mice during the initial phase of ganglion cell degeneration. At p82, however, 
cells of the INL in CLRSMαA mice displayed a marked increase in PAX6 protein 
levels. At this time point, the ganglion cell layer has lost about 75% of its cells 
(Fig. 2) and thus synaptic connectivity between bipolar-, amacrine- and ganglion 
cells was severely disrupted. We found similar results in total protein extracts of 
CLRSMαA mice. Western blots of PAX6 showed an increase of its expression at 
p72, reaching a peak at p82, with a progressive decline from p92 until normal 
levels at p102. 
In DBA/2J mouse, peak of RGC apoptosis varies between 6 and 11 months 
according to Schuettauf and Libby respectively.45,46 We speculate that in this 
mouse, PAX6 expression would have rised after the peak of GCL apoptosis. 
Although the length of time needed to obtain these results in DBA/2J was too 
long to be able to verify our hypothesis. 
In laser-induced ocular hypertension mouse model of glaucoma, IOP is less 
elevated than in CLRSMαA mice and induce a moderate RGC reduction of 15 to 
17% and 22 to 27% after 2 and 4 weeks respectively after laser photocoagula-
tion of the episcleral and limbal veins.32,33 We believe that in this mice, a slight 
elevation of PAX6 expression would have occured after 4 weeks but probably 
less pronounced than in our model because the apoptosis peak was less 
marked. Unfortunately, the cost of laser equipment precludes us from corrobo-
rating these data. We were less interested in studying PAX6 expression in RGC 
death following mechanical injury of the optic nerve,47 intraocular injection of 
excitotoxic agents48,49 or by the induction of ischemia followed by reperfusion 
50because the pathophysiology in those systems does not directly follow that of 
human glaucoma. 
It has been shown in models of photoreceptor degeneration that cells espe-
cially of the INL react to a loss of neurons by the induction of a program leading 
to retinal remodelling (for review see 51). Already during the initial phase of pho-
toreceptor loss, bipolar and horizontal cells are deafferented and retract most of 
their dendrites, and Muller cells increase the production of intermediate fila-
ments. Although remodelling processes in models of glaucoma have not been 
studied in detail, Marc and co-workers 51 showed that the space left by degen-
erated ganglion cells in RP retinas was filled at least in part by Muller cell end 
feet. Interestingly, Jones and co-workers have demonstrated that Pax6 expres-
sion is increased in cells of the INL during retinal degeneration in the rd1 
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mouse,29 concomitantly with the early phase of remodelling processes. Since 
Pax6 regulates eye development including retinal morphogenesis,52 it is con-
ceivable that increased Pax6 production during degeneration is required for 
surviving cells to adapt to the altered conditions by changing their cytoarchitec-
ture. This is supported by observations that expression levels of Pax6 can se-
verely influence the overall ocular structure. In the mouse eye for example, 
Pax6 overexpression leads to severe abnormalities like microphthalmia and 
cataract formation 53 and Glaser et al. have clearly shown a gene dosage effect 
of PAX6 in a human family in which different members were affected by PAX6 
mutations with either full or only partial transcriptional activity.54 
Taken together, our data show that retinal ganglion cell death induces the 
expression of Pax6 in cells of the INL. This suggests that Pax6 might be in-
volved in the maintenance of the cellular integrity after the loss of synaptic con-
nectivity and/or in processes required for the remodelling of the retinal cytoar-
chitecture after ganglion cell loss. Further studies looking at Pax6 expression in 
other mouse model of glaucoma would be interesting to confirm our findings, 
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Abstract 
Elevation of erythropoietin (Epo) concentrations by hypoxic preconditioning or 
application of recombinant human Epo (huEpo) protects the mouse retina 
against light-induced degeneration by inhibiting photoreceptor cell apoptosis. 
Because photoreceptor apoptosis is also the common path to cell loss in retinal 
dystrophies such as retinitis pigmentosa (RP), we tested whether high levels of 
huEpo would reduce apoptotic cell death in two mouse models of human RP. 
We combined the two respective mutant mouse lines with a transgenic line (tg6) 
that constitutively overexpresses huEpo mainly in neural tissues. Transgenic 
expression of huEpo caused constitutively high levels of Epo in the retina and 
protected photoreceptors against light-induced degeneration; however, the 
presence of high levels of huEpo did not affect the course or the extent of retinal 
degeneration in a light-independent (rd1) and a light-accelerated (VPP) mouse 
model of RP. Similarly, repetitive intraperitoneal injections of recombinant 
huEpo did not protect the retina in the rd1 and the VPP mouse. Lack of neuro-
protection by Epo in the two models of inherited retinal degeneration was not 
caused by adaptational downregulation of Epo receptor. Our results suggest 
that apoptotic mechanisms during acute, light-induced photoreceptor cell death 
differ from those in genetically based retinal degeneration. Therapeutic interven-
tion with cell death in inherited retinal degeneration may therefore require differ-
ent drugs and treatments. 
 
Keywords: retinal degeneration; erythropoietin; apoptosis; neuroprotection; 
photoreceptor; transgene 
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Introduction 
Retinitis pigmentosa (RP) and age-related macular degeneration (AMD) are 
major causes of severe visual impairment and blindness in the Western world. 
Common to both diseases is photoreceptor cell death by apoptosis (Portera 
Cailliau et al., 1994; Wong, 1994; Remé et al., 1998; Adler et al., 1999). Evi-
dence points to light as a cofactor accelerating the disease progression (Taylor 
et al., 1990; Cruickshanks et al., 1993, 2001 Simons, 1993; Cideciyan et al., 
1998), and some animal models for human retinal degenerations show higher 
light damage susceptibility than normal control animals (Sanyal and Hawkins, 
1986; Wang et al., 1997; Chen et al., 1999a,b; LaVail et al., 1999; Organisciak 
et al., 1999). Exposure to high levels of white light can thus be used as a model 
system to study signaling pathways during photoreceptor apoptosis and retinal 
degeneration (Remé et al., 1998). 
Recently we showed that hypoxic preconditioning stabilizes the -subunit of 
the hypoxia-inducible transcription factor-1 (HIF-1) in the retina. Subsequent 
binding of HIF-1 (for review, see Hopfl et al., 2004) to its heterodimerization 
partner HIF-1 induces the retinal expression of erythropoietin (Epo) and of other 
HIF-1 target genes and transiently protects the mouse retina against the damag-
ing effects of light exposure (Grimm et al., 2002). The application of recombi-
nant human Epo (huEpo) mimics the effect of hypoxia, demonstrating that Epo 
is a main component of the neuroprotection observed (Grimm et al., 2002). The 
protective effect of hypoxic (and hyperoxic) oxygen levels has also been dem-
onstrated in a rat model of continuous light exposure (Bowers et al., 2001), and 
the importance of oxygen and thus of oxygen-regulated tissue responses has 
been documented during retinal development, when physiological hypoxia may 
regulate cell death (Mervin and Stone, 2002). Furthermore, increased oxygen 
levels were shown to slow photoreceptor death in a rat model of retinal degen-
eration, whereas hypoxia accelerated cell death (Maslim et al., 1997; Valter et 
al., 1998). 
To test whether Epo might prevent retinal degeneration in models of inher-
ited retinal disease, we used a transgenic mouse line (termed tg6) that constitu-
tively overexpresses huEpo in an oxygen-independent manner preferentially in 
neuronal cells (Ruschitzka et al., 2000; Wiessner et al., 2001). Compared with 
wild-type (wt) controls, tg6 mice show 26-fold increased Epo levels in brain as 
well as a 12-fold elevation of Epo plasma levels (Wagner et al., 2001; Vogel et 
al., 2003). Here, heterozygous transgenic tg6 males were bred with two mouse 
models for human RP [for recent reviews on retinal degeneration animal mod-
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els, see Hafezi et al. (2000) and Chang et al. (2002)]. The rd1 mouse carries a 
mutation in the gene encoding the phosphodiesterase -subunit causing a fast 
and light-independent degeneration of photoreceptors (Bowes et al., 1990). The 
VPP transgenic mouse strain harbors three mutations (V20G, P23H, P27L) in 
the rhodopsin gene (Naash et al., 1993), one of which (P23H) represents the 
most common cause for autosomal-dominant RP in the United States. In the 
VPP mouse, retinal degeneration is accelerated by light but nevertheless pro-
ceeds slower than in the rd1 mouse (Goto et al., 1996; Naash et al., 1996). 
We show that transgene-derived Epo protects against photoreceptor apop-
tosis induced by acute light exposure. It does not protect against the mutation-
based degenerations in rd1 and VPP mice, however, although light is a cofactor 
accelerating photoreceptor degeneration in the latter. These results may be of 
importance with respect to potential clinical trials using Epo in patients with reti-
nal dystrophies. 
Material and methods 
Mice 
All procedures concerning animals were in accordance with the regulations of 
the Veterinary Authority of Zurich and with the statement of The Association for 
Research in Vision and Ophthalmology for the use of animals in research. 
Rpe65 variant at position 450 of the protein was determined by PCR using up-
stream primer 5’-CACTGTGGTCTCTGCTATCTTC-3’ and downstream primer 
5’-GGTGCAGTTCCACTTCAGTT-3’. The amplification product (674 bp) was 
digested with MwoI, which cuts the leucine variant yielding fragments of 236 and 
437 bp. MwoI does not cut the sequence encoding methionine. With the excep-
tion of tg6 and wt mice used in the light damage and rhodopsin regeneration 
study (heterozygous variant: Rpe65450Leu/Met; see Results), all mice used were 
homozygous for the Rpe65450Met variant. 
Induction and analysis of light damage 
Light damage was induced in dark-adapted 3-, 4-, and 6- to 8-week-old mice 
with dilated pupils by exposure to 13 klux of diffuse white fluorescent light for 
120 min as described (Grimm et al., 2000). After 24 hr in darkness, the extent of 
light damage was determined in the right retina using the Cell Death Detection 
Kit (Roche Diagnostics, Basel, Switzerland) according to the manufacturer’s 
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recommendation, and in the left eye the extent of light damage was determined 
by light microscopy as described (Kueng-Hitz et al., 2000). 
Rhodopsin content and regeneration 
The rhodopsin content was determined as described (Kueng-Hitz et al., 2000). 
Dark levels of rhodopsin were measured after 16 hr of dark adaptation. To as-
sess rhodopsin regeneration, dark-adapted mice, with dilated pupils, were ex-
posed to white light (10 min, 5 klux). Rhodopsin was measured either immedi-
ately after light exposure or at 45 min in darkness. 
Western blotting and ELISA 
Retinas were homogenized in 100 mM Tris/HCl, pH 8.0, and analyzed for pro-
tein content using Bradford reagent. Standard SDS-PAGE and Western blotting 
were performed. For immunodetection, polyclonal rabbit anti-Epo receptor anti-
bodies (sc-697; Santa Cruz Biotechnology, Santa Cruz, CA) were applied, fol-
lowed by an HRP-conjugated secondary anti-rabbit antibody (sc-2004; Santa 
Cruz Biotechnology), and immunoreactivity was visualized using the Renais-
sance-Western blot detection kit (PerkinElmer Life Sciences, Emeryville, CA). 
Epo levels were determined with an ELISA kit according to the manufac-
turer’s recommendations (R & D Systems, Minneapolis, MN). 
Immunohistochemistry 
Eyes were enucleated and fixed in 2.5% glutaraldehyde/0.1 M phosphate buffer, 
pH 7.4, for 4 hr at 4°C. Eyecups were cut temporal to nasal through the optic 
nerve head. Trimmed tissue was washed twice in 0.1 M phosphate buffer, pH 
7.4, for 15 min followed by dehydration and embedding in Epon 812. Epoxy 
resin of 0.5 µm tissue sections was removed by incubation for 7 min at room 
temperature in etching solution (2.4 M KOH, 66.6% methanol, 33.3% propylene 
oxide). Slides were washed once in 100% methanol, once in 50% methanol/0.5x 
PBS, and twice in PBS for 5 min. Tissue was preincubated for 30 min with 10% 
normal goat serum (NGS) in PBS at room temperature followed by an overnight 
incubation with the primary anti-Epo antibody (AB-286-NA, 1:200; R & D Sys-
tems) in 3% NGS at 4°C. Slides were washed three times with PBS for 10 min 
each. Tissue was preincubated for 30 min in 10% NGS at room temperature. 
Cy3-conjugated anti-rabbit secondary antibody (Jackson ImmunoResearch, 
West Grove, PA) was applied for 80 min in 3% NGS at room temperature. Sec-
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tions were washed three times in PBS for 10 min each. Staining was analyzed 
with a fluorescence microscope (Axiovision, Zeiss) and documented using a 
digital imaging system. 
Epo injections 
One hundred international units of Epo (Recormon 2000; Roche, Basel, Switzer-
land) in 0.9% NaCl were injected intraperitoneally at postnatal day 11 (P11) (rd1 
only), P13, P15, P17, and P19. 
Results 
Overexpression and localization of huEpo in the retina HuEpo was expressed 
at highly elevated levels in the retina early during postnatal development in tg6 
as well as in tg6/rd1 and tg6/VPP double-mutant mice (Table 1). The huEpo 
transgene expression localized mainly to the inner segments of photoreceptor 
cells: the outer nuclear layer (ONL), inner nuclear layer (INL), and ganglion cell 
layer (GCL). This localization was comparable with the endogenous Epo pre-
sent in the wt retina (Fig. 1A, B). The labeling was specific, because no signal 
was detected when the primary antibody was omitted (Fig. 1C) or when the 
immunoreaction was competed by preincubating the primary antibody with 
huEpo (data not shown). Expression of the transgene did not influence retinal 
morphology in tg6 mice (Figs. 1, 2, 5), suggesting that high levels of Epo and 
excessive erythrocytosis do not affect postnatal retinal development and devel-
opmental apoptosis. 
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Figure 1. Expression and localization of Epo in the mouse retina. Retinas of wt (A, C) and tg6 
(B) mice were fixed and stained using an antibody specific for Epo. Control was a wt retina 
incubated without primary antibody (C). Both endogenous Epo and huEpo expressed from the 
transgene in tg6 localize to the ONL, INL, and GCL. PE, Pigment epithelium; ROS, rod outer
segments; RIS, rod inner segments; ONL, outer nuclear layer; INL, inner nuclear layer; GCL,
ganglion cell layer. Scale bar, 25 µm. 
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Table 1. Average Epo levels in retinas of wt, tg6, rd1, VPP, rd1/tg6, and VPP/tg6 mutant mice at 
different postnatal days as indicated 
Strain Postnatal days Epo (mIU/100 µg)  
wt 11  0.38  
tg6 11  8.26  
rd1 11  0.24  
VPP 11  <0.002  
rd1/tg6 11  9.48  
VPP/tg6 11 11.66  
wt 21  0.16  
tg6 21  3.75  
rd1 21  0.02  
VPP 21  0.04  
rd1/tg6 21 14.78  
VPP/tg6 21  9.92  
wt 37  0.16  
tg6 37  3.89  
rd1 37  <0.002  
VPP 37 ND  
rd1/tg6 37  8.19  
VPP/tg6 37 ND  
ND, Not determined. n = 2–5 retinas. 
Overexpression of Epo protects against light-induced retinal degeneration 
Elevation of endogenous Epo levels by hypoxic preconditioning or exogenous 
application of recombinant huEpo protects against light-induced retinal degen-
eration (Grimm et al., 2002). Therefore, we tested whether high levels of huEpo 
constitutively expressed from the Epo transgene in tg6 mice would also be pro-
tective against light damage. After exposure to 13 klux of white light for 2 hr, cell 
death was firmly reduced in tg6 mice as compared with wt littermates (Fig. 2A-
F). In wt animals, light exposure induced photoreceptor cell death in a large 
central area, with almost all photoreceptor nuclei showing condensed chromatin 
after 24 hr, an indicator of ongoing apoptosis (Fig. 2C). In contrast, the affected 
area in tg6 mice was smaller, and not all photoreceptor nuclei were pyknotic, 
even in the most affected region (Fig. 2D). When retinal morphology was ana-
lyzed 12 d after light exposure, wt mice showed one to two rows of surviving 
photoreceptor nuclei (Fig. 2E), whereas tg6 retinas retained four to five rows in 
the most affected region. In addition, morphology of photoreceptor inner and 
outer segments was better preserved in tg6 mice (Fig. 2F). At 12 d after illumi-
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nation, photoreceptor apoptosis is completed, and the remaining photoreceptors 
are stable (our unpublished observation). The larger survival rate of tg6 photo-
receptors 12 d after light exposure is reflected by the increased rhodopsin con-
tent of transgenic retinas (92 ± 2.3% of untreated controls; n = 3) as compared 
with wt littermates (76 ± 12% of untreated controls; n = 3). 
 
Figure 2. Light-induced retinal degeneration 
in wt and tg6 mice. A, Nonexposed wt retina. 
B, Nonexposed tg6 retina. C, Most affected 
retinal area of a wt mouse 24 hr after light 
exposure showing severe destruction of 
photoreceptor outer and inner segments () 
and condensed nuclear chromatin (*). D, Most 
affected retinal area of a tg6 mouse 24 hr 
after light exposure. Lesions are qualitatively 
similar but distinctly less severe and the 
number of pyknotic nuclei is reduced. E, Most 
affected retinal area of a wt mouse 12 d after 
light exposure. One to two rows of photore-
ceptor nuclei are left. F, Most affected retinal 
area of a tg6 mouse 12 d after light exposure. 
Four to five rows of photoreceptor nuclei are 
left. Affected region is smaller than in the wt 
(data not shown). G, Extent of light damage in 
retinas of tg6 mice at ages indicated. Damage 
is expressed in percentage of damage in 
littermate control mice of corresponding ages. 
Damage was determined by ELISA-based 
measurement of cytoplasmic nucleosomes. 
Values in wt were set as 100%. Number of 
animals: n = 3–6. Abbreviations are given in 
Figure 1 legend. Scale bars, 25 µm. 
 
The morphological examination of the retina identifies the area of lesion and cell 
types that are affected but restricts the analysis to a small tissue fraction. There-
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fore, we used the ELISA-based quantification of free cytoplasmic nucleosomes 
(as they occur during the course of apoptosis) to determine the extent of cell 
death in a whole retina. Measurements in light-exposed retinas of 6- to 8-week-
old tg6 animals showed a reduced number of cytoplasmic nucleosomes as 
compared with wt mice. According to this number, damage was calculated to be 
36% of that of wt (Fig. 2G). The reduction in damage reflects the extent of pro-
tection observed in the morphological analysis of tg6 retinas. Because photore-
ceptor degeneration in the inherited models occurs at an earlier age, we tested 
the responsiveness of younger retinas to Epo-mediated neuroprotection. The 
presence of the Epo transgene reduced the retinal susceptibility to light-induced 
degeneration and protected the photoreceptors to a similar level (36–46%) at all 
ages tested (Fig. 2G). Interestingly, 3- and 4-week-old retinas were markedly 
less sensitive to light than older retinas (data not shown). 
Tg6 and wt littermates showed light damage only when at least one allele of 
the Rpe65 gene carried the Rpe65450Leu variant (data not shown). The 
Rpe65450Leu variant increases steady-state levels of the RPE65 protein and the 
rate of rhodopsin regeneration (Wenzel et al., 2001). This observation further 
supports the important role of Rpe65 in the regulation of light damage suscepti-
bility in mice. All mice used in the light damage and rhodopsin (see below) ex-
periments were offspring from crosses between male tg6;Rpe65450Met and fe-
male Rpe65450Leu and therefore were heterozygous for the variant in the Rpe65 
gene (Rpe65450Met/Leu). 
Because rhodopsin regeneration is an important determinant of light dam-
age susceptibility (Wenzel et al., 2001), we tested whether the presence of high 
Epo levels in the tg6 retina might influence rhodopsin regeneration in the visual 
cycle. Tg6 mice and wt littermates had similar dark-adapted levels of rhodopsin 
(0.48 ± 0.06 nmol per retina for the wt and 0.48 ± 0.03 nmol per retina for tg6; n 
= 6 retinas). Furthermore, bleaching efficiency was identical in both animals 
(rhodopsin remaining after a 10 min bleach: 0.05 ± 0.01 nmol per retina for wt 
and 0.05 ± 0.01 nmol per retina for tg6; n = 6 retinas), and regeneration of 
rhodopsin in darkness was indistinguishable between wt and tg6 (rhodopsin 
levels after 45 min of regeneration in darkness: 0.28 ± 0.03 nmol per retina for 
wt and 0.26 ± 0.05 nmol per retina for tg6; n = 6 retinas). These results strongly 
suggest that the presence of high Epo levels in the tg6 retina did not alter known 
parameters for light damage susceptibility but directly protected photoreceptor 
cells against apoptosis induced by acute light exposure. 
C h a p t e r  4  
 91 
Effect of high Epo levels on inherited retinal degeneration 
To test a potential protective effect of Epo in inherited retinal degeneration, we 
crossed the Epo transgenic mice with two mouse models for human RP. The 
rd1 mouse carries a nonsense mutation in the gene encoding the phosphodi-
esterase subunit (Bowes et al., 1990). This induces a rapid and light-
independent degeneration of the photoreceptor cell layer starting around P10. 
The VPP mouse carries a transgene with three mutations in the rhodopsin gene 
(V20G, P23H, P27L), causing a dominant but slow degeneration of the photore-
ceptor cell layer (Naash et al., 1993). In wt, rd1, and VPP retinas, Epo was ex-
pressed at low levels at P11 that dropped to almost nondetectable levels at P21 
and at P37 (Table 1). The presence of the Epo transgene increased retinal Epo 
levels >20-fold in rd1 and VPP mice (Table 1). With increasing age, levels of 
Epo decreased in all groups of mice, but the presence of the transgene never-
theless sustained highly elevated Epo levels. 
Similar to Epo, the Epo receptor was expressed at P11 in wt, tg6, rd1, and 
VPP retinas (Fig. 3A, B); however, expression of the receptor was decreased at 
P21 in both rd1 and VPP retinas. The levels decreased to almost nondetectable 
levels in the rd1 retina at P62 but remained expressed in the VPP retina. Be-
cause the Epo receptor localizes mainly to photoreceptor cells (Grimm et al., 
2002), the decrease probably reflects the loss of photoreceptors in the two 
mouse models (compare Figs. 4, 5). This loss is much more pronounced in the 
rd1 mouse with no photoreceptors left at P62 (data not shown). Thus, the re-
maining weak signal at P62 in the rd1 mouse (Fig. 3C) might be attributable to 
expression of the receptor in ganglion cells and amacrine neurons as suggested 
by Junk and colleagues (2002). Despite the expression of the Epo receptor at 
the onset of the degenerative process (P11), the presence of high levels of Epo 
did not rescue photoreceptors from cell death in the rd1 mouse (Fig. 4). Retinal 
degeneration proceeded without notable differences in rd1 and double-mutant 
rd1/tg6 mice. A single layer of photoreceptor cells (mostly cones) was visible at 
P21 and P37. 
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Figure 3. Expression of Epo receptor in the retina. Total retinal homogenates were tested by
Western blotting for the presence of Epo receptor. A, Epo receptor in wt, tg6, rd1, and VPP retinas 
at different postnatal days as indicated. B, Direct comparison of Epo receptor between wt and tg6 
retinas showing no downregulation by the overexpression of Epo in tg6 at least up to P37. C, 
Overexposure of retinal samples of rd1 mice at P21 and P62, respectively, showing a small frac-
tion of Epo receptor remaining at P62. 
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Figure 4. huEpo transgene expression does not rescue photoreceptor cells in the rd1 mouse.
Retinal morphology at P11 (A-D), P21 (E-H), and P37 (I-L) of wt (A, E, I), tg6 (B, F, J), rd1 (C, G, 
K), and rd1/tg6 double-mutant mice (D, H, L). Compared with wt and tg6 retinas, the outer seg-
ments in rd1 and rd1/tg6 mice are less developed, and both rd1 and rd1/tg6 retinas show scattered 
apoptotic nuclei at P11 and almost complete loss of photoreceptors at P21 and P37. Representa-
tive sections of two to four animals per time point and mouse strain are presented. Abbreviations 
are given in Figure 1 legend. PND, Postnatal day. Scale bar, 25 µm. 
 
Similarly, retinal degeneration was not influenced by the Epo transgene in the 
VPP mouse (Fig. 5). At 3 weeks of age, the ONL thickness in VPP and VPP/tg6 
mouse lines was approximately half of that in control littermates. Degeneration 
proceeded slowly in both strains, and at 8 weeks of age, only one to two addi-
tional rows of photoreceptor nuclei were lost. In contrast to the decreasing num-
ber of photoreceptor cells, morphology of the inner and outer segments in the 
VPP and VPP/tg6 strains improved between postnatal weeks three and six. This 
observation was confirmed by retinal rhodopsin measurements (Fig. 6). Al-
though rhodopsin levels in wt and tg6 strains were at normal levels throughout 
the experimental period, rhodopsin contents of the VPP retinas (independently 
of the presence or absence of the Epo transgene) were reduced at 3 weeks of 
age and increased until postnatal week 6 before levels decreased again. 
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Figure 5. huEpo transgene expression does not rescue photoreceptor cells in the VPP mouse.
Retinal morphology at 3 weeks (A-D), 4 weeks (E-H), 6 weeks (I-L), and 8 weeks of age (M-P) of wt 
(A, E, I, M), tg6 (B, F, J, N), VPP (C, G, K, O), and VPP/tg6 double-mutant mice (D, H, L, P). Repre-
sentative sections of two to four animals per time point and mouse strain are presented. Photore-
ceptor degeneration proceeded similarly in VPP and VPP/tg6 retinas. Abbreviations are given in 
Figure 1 legend. Scale bar, 25 µm. 
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Figure 6. Effect of huEpo overexpression on rhodopsin levels (in nanomoles per retina) in wt and
mutant mouse retinas at ages [weeks (wks)] indicated. Rhodopsin is representative for amount and 
integrity of rods. Given are mean values ± SD of the rhodopsin content of at least n = 3 retinas. 
 
To circumvent potential long-term side effects of the sustained Epo expression 
from the Epo transgene used in the above experiments (see Discussion), we 
repetitively injected 100 IU of recombinant huEpo intraperitoneally into rd1 and 
VPP mice at P11 (rd1 only), 13, 15, 17, and 19. The dosage used (100 IU per 
injection) was shown to protect retinal photoreceptors against light damage after 
a single injection (Grimm et al., 2002). At P21, mice were killed and analyzed. 
The Epo-injected mice showed hematocrit values elevated by 41% (VPP; n = 4) 
and 40% (rd1; n = 11) on average compared with sham-injected mice. This con-
firms that the applied Epo was biologically active; however, retinal morphology 
was not detectably rescued in the rd1 (Fig. 7A) and the VPP (Fig. 7B) mice, and 
rhodopsin levels were either not detectable (rd1; data not shown) or did not 
differ from untreated controls (VPP) (Fig. 7C). 
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Figure 7. Effect of huEpo injections on retinal morphology and rhodopsin levels at PND 21. A, 
Retinal morphology of rd1 mice after NaCl injections (top panel) or Epo injections (bottom panel)
applied at PND 11, 13, 15, 17, and 19. B, Retinal morphology of VPP mice after NaCl injections (top 
panel) or Epo injections (bottom panel) applied at PND 13, 15, 17, and 19. C, Rhodopsin content of 
VPP retinas with or without repetitive treatment (injections) of huEpo (n = 4). Abbreviations are 
given in Figure 1 legend. Scale bar, 25 µm 
Discussion 
We showed recently that increased retinal levels of Epo (induced either by hy-
poxic preconditioning or by intraperitoneal injection of recombinant huEpo) pro-
tect the retina against degeneration induced by acute exposure to high intensity 
light (Grimm et al., 2002). Furthermore, Epo protected retinal ganglion cells from 
cell death after experimental ischemia (Junk et al., 2002). Therefore, Epo be-
came a candidate drug for the treatment of inherited retinal degenerative dis-
eases such as retinitis pigmentosa in human patients. 
Here we show that Epo has the capacity to protect the retina against light 
damage also when expressed from a transgene. Thus, with regard to its neuro-
protective potential, transgenically overexpressed huEpo protein is comparable 
with systemically applied recombinant huEpo. To test whether Epo can also 
protect retinal cells in inherited retinal degeneration, we crossed the transgene 
into two mouse models for human RP. In both the rd1 and the VPP mouse, the 
transgene caused highly increased levels of Epo in the retina but did not inhibit 
cell death and retinal degeneration. Similarly, exogenous application of huEpo 
also did not delay cell death in the two mouse models of human RP used. This 
lack of protection indicates that Epo cannot interfere with the death signal in-
duced by the respective gene mutations. 
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It has been shown that increased oxygen levels (hyperoxia) slow photoreceptor 
death in a rat model of retinal degeneration [Royal College of Surgeons (RCS) 
rat] and that reduced oxygenation accelerates disease progression (Maslim et 
al., 1997; Valter et al., 1998). This suggests a critical role of retinal oxygen levels 
in the regulation of cell death. Epo-overexpressing tg6 mice have increased 
blood volumes (up to 25% of body weight) (Vogel et al., 2003) and hematocrit 
values (up to 83%) (Ruschitzka et al., 2000) twice as high as wt mice. Because 
the arterial PO2 is not altered, the arterial oxygen content is increased, thereby 
implying elevated oxygenation of all organs, including the retina. Nevertheless, 
retinal degeneration in the rd1 and the VPP mouse was not influenced, suggest-
ing that mechanisms different from those in the RCS rat may account for the 
photoreceptor cell death in the two mouse models. 
Despite their highly increased blood volume and hematocrit value, tg6 mice 
do not show an elevated risk for thromboembolism (Wiessner et al., 2001). Ob-
viously, the life-long exposure to high Epo levels provoked adaptative mecha-
nisms including nitric oxide-mediated vasodilation (Ruschitzka et al., 2000; Vo-
gel et al., 2003) as well as regulated elevation of blood viscosity by increasing 
erythrocyte flexibility (Quaschning et al., 2003; Shibata et al., 2003). It is there-
fore feasible that the prolonged exposure to high Epo levels in tg6 might possi-
bly desensitize the Epo-Epo receptor (EpoR) system in the retina, reducing the 
neuroprotective capacity of Epo; however, a potential desensitization of the Epo 
system was not obvious in our model system. The Epo receptor was highly ex-
pressed in the retina as early as at P11 in all strains tested, and Epo receptor 
levels in tg6 and wt mice remained comparably high at least until day 37. Fur-
thermore, the Epo transgene protected the retina against light damage to a simi-
lar extent, independently of the age of the animals (Fig. 2). Although retinas of 
young mice were less susceptible to light damage in general, the presence of 
high Epo levels further reduced the severity of retinal degeneration after light 
exposure. This shows that Epo can already confer neuroprotection in young 
retinas, at a time when retinal degeneration is ongoing at least in the VPP 
model. These results suggest that constitutively high levels of Epo did not down-
regulate expression of Epo receptor as an adaptative measure in the tg6 retina 
and that a desensitization of the Epo-EpoR system did not occur. 
Although Epo protects against light damage (Fig. 2) (Grimm et al., 2002), 
Epo did not improve photoreceptor cell survival and retinal pathology in the VPP 
mouse, although progression of the degeneration of the VPP retina is acceler-
ated by light (Naash et al., 1996). Light as pathogenic stimulus uses at least two 
different pathways to induce the apoptotic program. Activation and choice of a 
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particular pathway seem to depend on the intensity and duration of light expo-
sure (Hao et al., 2002). Thus, a compound effective in the protection against 
acute bright light, such as Epo, may not necessarily be protective against long-
lasting low-level light exposure. Such a prolonged exposure to low-level light 
may be the cofactor accelerating the degeneration mediated by the VPP muta-
tions. Differences in signaling between light-induced and inherited retinal de-
generation are also evidenced by the observed differential effect of several sur-
vival factors (LaVail et al., 1998) and other compounds such as nitro-L-arginine 
methyl ester (Kaldi et al., 2003) or the free radical trap phenyl-N-tert butylnitrone 
(Ranchon et al., 2003) on light-induced and inherited retinal degeneration in 
mice and rats. 
Different apoptotic pathways may exist in various models of retinal degen-
eration and a potential systemic or local adaptation to high Epo levels might 
affect one but not another anti-apoptotic pathway. To address such a possibility, 
we applied huEpo exogenously. As shown previously, intraperitoneally injected 
huEpo reaches the retina where it can protect the retina against light damage 
(Grimm et al., 2002). The repeated systemic application of huEpo increased 
hematocrit values of the injected animals, showing that the protein was biologi-
cally active; however, the injected Epo could not inhibit cell death in the rd1 or 
VPP retina. This supports the conclusion that adaptational changes, whether 
systemic or local, might not be the reason for the lack of protection expressed 
from the transgene. More likely, signaling pathways and apoptotic mechanisms 
differ between acute light damage and the two models of inherited retinal de-
generation to such a degree that Epo can prevent cell death in one but not the 
other model. It has been shown for other factors (e.g., CNTF or BDNF) that dif-
ferent models are amenable in different ways to a treatment with cytokines 
(LaVail et al., 1998). At the present time, our data suggest that Epo alone might 
not be sufficient for a successful therapeutic intervention with cell death in inher-
ited retinal degeneration. On the other hand, encouraging results after Epo 
treatment have been reported on three patients with diabetic retinopathy and 
renal failure (Berman and Friedman, 1994; Friedman et al., 1995). 
We observed that protection by transgenically expressed (or exogenously 
applied) Epo was less efficient as compared with hypoxic preconditioning, sug-
gesting that other hypoxia-inducible factors may act in concert with Epo to con-
fer the complete protection observed after hypoxic exposure. It has been shown 
in other systems that treatment with a combination of growth factors or cytokines 
improves the retinal morphology in vivo and in vitro as compared with admini-
stration of the individual factors alone (Ogilvie et al., 2000; Caffe et al., 2001; 
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Cao et al., 2001). Thus, the possibility exists that additional hypoxia-inducible 
factors might act together with Epo to achieve full neuroprotection. In keeping 
with this, we will test whether a successful retinal treatment with Epo requires a 
combination with other cytokines or growth factors.  
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Abstract 
Purpose: In the past few years, the essential role of the homeobox gene PAX6 
for eye development has been demonstrated unambiguously in a variety of 
species including humans. In humans, PAX6 mutations lead to a variety of ocu-
lar malformations of the anterior and posterior segment. However, little is known 
about PAX6 expression in the adult human retina. We have therefore investi-
gated PAX6 levels and localization in the human retina at various ages. 
Methods: Adult human eyes of various ages (17–79 years) were obtained from 
the Zurich Eye Bank. PAX6 expression levels and patterns were analysed by 
Western blot analysis of total retinal protein and by immunohistochemistry on 
paraffin sections, respectively. 
Results: PAX6 expression in the retina was detected up to 79 years of donor 
age and was predominantly localized to the ganglion cell layer and the inner 
part of the inner nuclear layer. 
Conclusions: PAX6 remains distinctly expressed throughout the lifespan of the 
human retina suggesting a role for PAX6 in the retina after completion of eye 
morphogenesis. 
 
Keywords: foveal hypoplasia, PAX6, human, aniridia, Peter’s anomaly 
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Introduction 
The homeobox gene PAX6 is an essential regulatory element for ocular devel-
opment in a variety of species with special emphasis on mammals.1 The pre-
dominant role of PAX6 even in different animal phyla such as insects and verte-
brates is demonstrated by the high rate of conservation of PAX6 domains 
throughout evolution, as demonstrated by a 93% homology of the PAX6 amino 
acid sequence between Drosophila and human over the paired domain and the 
homeodomain.2 
In humans, PAX6 has been mapped to chromosome 11p13 and is ex-
pressed mainly in the eye, brain, and pancreas during development. In the last 
years, a number of human PAX6 mutations have been identified leading to a 
variety of ocular malformations of the anterior and posterior segment.3-11 
In the developing human retina, PAX6 expression can be histochemically 
detected in the Inner Nuclear Layer and Ganglion Cell Layer, as demonstrated 
by Nishina et al 12 in human foetuses up to gestation week 22. 
Interestingly, research on expression patterns and regulatory function of 
PAX6 had focused on developmental stages solely and little is known about the 
role of PAX6 in the ageing mammalian retina. We have recently shown that in 
the mouse retina, PAX6 is constantly expressed throughout the whole lifespan 
of the animal. Furthermore, we have demonstrated that PAX6 is downregulated 
in two animal models for retinal degeneration during the peak of photoreceptor 
apoptosis (Iseli et al, submitted). To analyse whether PAX6 expression in the 
human retina persists after the end of ocular development, we performed West-
ern Blot analyses and immunohistochemical studies on human retinas at vari-
ous ages. 
Material and methods 
Dissection of retinas 
Human retinas were obtained from seven eyes from donors aged 17–79 years. 
Eyes were provided by the Zurich Eye Bank as globes with excised cornea, the 
latter being further processed for corneal grafting. The procurement and use of 
human tissues in this study complied with the Declaration of Helsinki. Causes of 
death included myocardial infarction, cerebral vascular accident, renal insuffi-
ciency, multiple organ failure, aortic dissection, and congestive heart failure. 
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Time between death and enucleation was below 12 h and time between death 
and dissection was below 14 h in all samples (Table 1). Prior to dissection, the 
posterior pole was inspected through an operating microscope to confirm the 
absence of gross retinal disease. The central retina was defined as the region 
delimited by the optic nerve nasally, the retinal arcuate vessels superiorly and 
inferiorly and an imaginary line 2 mm temporally of the fovea. All retinas were 
dissected on ice. Briefly, corneas were excised and vitreous was extruded with 
a forceps. Retinas were gently removed from the retinal pigment epithelium 
(RPE) with a smooth forceps at the ora serrata and the optic nerve head. Care 
was taken that retinal tissue was free from RPE remnants. Central retinal tissue 
was frozen in liquid nitrogen and stored at -80°C. All samples used in this study 
were free of malignancies or any known ocular disease. 
 
Table 1. Human donor information 
Sample Age 
(years) 
Sex TDE (h) TDF Cause of death 
1 17 F  9 13 Polytrauma 
2 28 M 12 12 Polytrauma 
3 36 M  5  8 Myocardial infarction 
4 45 M  7  9 Myocardial infarction 
5 55 M  9 13 Renal failure 
6 66 M  6  9 Cerebral vascular accident 
7 79 F  8 11 Cerebral vascular accident 
GW=gestation week; TDE=time between death and enucleation; TDF=time between death and 
fixation. 
Western blotting 
Human retinas were homogenized in 100 mM Tris-Hcl, pH 7.4 using a sonifier. 
Protein concentrations were determined by the Bradford assay using BSA as 
standard. Western blotting was performed according to standard protocols. For 
immunodetection, polyclonal rabbit antisera directed against PAX6 were ap-
plied.13 After application of HRP-conjugated secondary antibodies, immunoreac-
tivity was visualized using the Renaissance-Western blot detection kit (Perkin-
Elmer Life Sciences, Emeryville, USA). 
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Immunohistochemical analysis 
For IHC, whole eyecups were fixed by immersion in 4% paraformaldehyde in 
100 mM PBS (pH 7.4) overnight and processed to paraffin blocks using stan-
dard protocols. Sections (10 m) were deparaffinized in xylene and dehydrated in 
descending ethanol series. To enhance immunoreactivity, sections were incu-
bated in 10 mM citrate buffer (pH 6.0) and boiled in a steamer at 100°C for 
3 min. For immunofluorescence primary polyclonal rabbit antibodies for the 
detection of Pax6 were used at dilutions of 1 : 300 (Covance, Princeton, NJ, 
USA) or 1 : 200 (Chemicon, Temecula, CA, USA) overnight at 4°C, and visual-
ized via biotinylated secondary antibodies (goat anti-rabbit; 1 : 200; Vector 
Labs, Burlingame, CA, USA) and streptavidin-Cy3 (1 : 200; Sigma-Aldrich, St 
Louis, MO, USA). Absence of the primary antibody was used as negative con-
trol (data not shown). 
Results 
Specificity of the antibody was examined by Western blot analysis. Blots display 
a band with a molecular weight of 46 kDa and a second band of 48 kDa corre-
sponding to the splicing isoform of PAX6, PAX6(5a). As an internal control la-
belling with an antibody against actin was performed. Actin levels remained 
constant throughout all time points tested in all experiments performed (data not 
shown). 
Persistent expression was detected at all ages tested: 17, 28, 36, 45, 55, 
66, and 79 years with varying levels of expression as shown in Figure 1. 
Immunohistochemical analysis is shown in Figure 2a and reveals that PAX6 
expression in the retina is confined to the ganglion cell layer (GCL) and the 
inner portion of the inner nuclear layer (INL). 
 
 
Figure 1. Western blot analysis of PAX6 expression and its alternative splice forms in human 
retinas at various ages (17, 28, 36, 45, 55, 66, and 79 years). Expression was detected at all ages 
tested with varying levels. 
C o n t i n u o u s  e x p r e s s i o n  o f  t h e  h o m e o b o x  g e n e  P a x 6 …  
 108 
 
Figure 2. Positive PAX6 immunostaining (a) of nuclei in the INL (arrow) and GCL (arrowhead) of 
the inner human retina. outer nuclear layer (ONL); inner nuclear layer (INL); ganglion cell layer 
(GCL) 
Discussion 
In humans, a number of heterozygous PAX6 mutations has been identified in 
the last years leading to a large variety of different ocular disorders and malfor-
mations of both the anterior and posterior segment. These disorders range from 
autosomal dominant keratitis, congenital cataract, Peter’s anomaly and aniridia 
to isolated foveal hypoplasia,3-11 for review see.14 Furthermore, homozygous 
human PAX6 mutations lead to anophtalmia, brain malformation, and early 
postnatal death.15 Little is known about PAX6 expression in the adult human 
retina: Nishina et al12 have studied PAX6 expression in human foetuses until 
gestation week 22 and histochemically detected PAX6 expression in the INL 
and GCL. 
Similarly, in mice, homozygous mutations of the Pax6 homologue small eye 
(sey) lead to a distinct phenotype with early postnatal death and absence of 
eyes whereas heterozygous (sey/+) mutations show microphthalmia and cor-
neal, chamber angle and lenticular abnormalities16,17 with striking similarities to 
the human condition.5,8,15,18 
 
There is growing evidence that the two major isoforms of PAX6, PAX6(+5a) and 
PAX6(-5a) may play different biological roles: Dominguez et al19 have shown 
lately that in Drosophila PAX6(+5a) functions primarily in the regulation of 
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growth and less effectively in eye specification than PAX6(-5a). Furthermore, 
the PAX6(+5a) isoform is involved in the chain of events leading to formation of 
the fovea centralis in the developing chick eye whereas PAX6(-5a) is not.20 Our 
human data show expression of both isoforms in the retina with varying levels. 
To test whether PAX6 is also expressed in the ageing human retina we 
have analysed the retinas of six individuals of different ages up to 79 years by 
Western blot analysis and immunohistochemistry and found a persistent retinal 
expression of PAX6 with localization to the inner retina, similar to the embry-
onic12 condition. Equal amounts of total retinal protein were loaded as verified 
by tubulin control blots (data not shown). Nevertheless, PAX6 expression varied 
markedly between different sample ages. This might either be due to different 
degrees of protein degradation in post mortem eyes or it might represent inter-
individual changes in protein expression levels. 
The question remains why a master gene of development is expressed in 
an ageing tissue. To address this question, Walter Gehring and collaborators 
have performed an experiment in the ribbonworm Lineus where they sup-
pressed PAX6 expression in the adult eye by RNA interference: 37 days after 
suppression of PAX6, the eyes disappeared (W Gehring, personal communica-
tion). 
Furthermore, we have recently shown that in wild-type mice, PAX6 expres-
sion in the inner retina persists during the whole lifespan of animals. Interest-
ingly, PAX6 is downregulated in two different animal models for retinal degen-
eration during the peak of retinal apoptosis (Iseli et al, submitted). 
In light of the striking similarities of PAX6 mutations in mice and men, our 
findings in the human retina suggest a potential role for PAX6 in the human 
retina after completion of eye morphogenesis. 
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Introduction 
PAX6 is the master gene for eye development and its indispensable for the 
formation of all the structures of the eye until completion at adulthood.1 
Little is known about its expression and its role in adulthood once the eye 
formation is finished. We know that PAX6 null mutation is lethal in both mice 
and human.2-4 Homozygous murine small eye (Sey) mutations lead to a distinct 
phenotype similar to that seen in human PAX6 null mutation. They die immedi-
ately after birth lacking eyes, nasal cavities and with severe brain abnormalities, 
including a malformed cerebral cortex.2,5 Heterozygous mutations of PAX6 lead 
to severe ocular abnormalities in human from the anterior segment to the poste-
rior segment of the eye including the optic nerve. Aniridia is the most common 
manifestation of PAX6 mutation.3,6-27 Keratitis,3,38 Peters anomaly,39,40 pre-senile 
cataract,3,41 foveal hypoplasia,42 optic nerve coloboma and other optic nerve 
malformations43 are part of the spectrum of different heterozygous mutations of 
PAX6 in humans. In mice, Sey, the murine equivalent of PAX6 gene, and its 
heterozygous mutations Sey +/- results in the small eye phenotype consisting in 
microphthalmia, corneal and lenticular abnormalities.39,44,45 
Pax6 over-expression after ocular development 
Interestingly, higher than normal levels of Pax6 produce complex phenotypes in 
which several features of eye morphogenesis are affected. Indeed, mice carry-
ing multiple copies of Pax6 on a wild-type background show specific develop-
mental abnormalities of the eye consisting in microphthalmia, corneal abnor-
malities, cataract, a disorganized ciliary body and absence of photoreceptor 
layer of the retina.46 
Both increased and decreased Pax6 gene dosage result in defective eye 
development, but the effects are quite different. Whereas defects of Pax6+/- 
mice occur mainly in the anterior segment of the eye, over-expression of Pax6 
causes major defects of retinal development resulting in results in microphthal-
mia, retinal dysplasia and defective retinal ganglion cell axon guidance.47 
Little is known about PAX6 gene and PAX6 protein after ocular develop-
ment in mammalians. Previous reports have shown that PAX6 was present in 
the mature retina of goldfish,48 quail,49 and pig.50 PAX6 was found in the cornea 
and conjunctiva of adult mice and believed to play a role in the cyto-architecture 
of these tissues. Two isoforms of PAX6 gene, PAX6 and PAX6(5a) protein, 
were found in both adult monkey retina and adult human lens epithelium cells. It 
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was suggested that PAX6 might play a role of in the adult lens maintenance and 
cataract formation through activation of Beta-crystallins genes.51 Based on 
these findings in the literature we hypothesize the presence of Pax6 in both 
adult mouse and human in the retina. 
We discovered that PAX6 gene and its protein PAX6 was not only present 
in the retina during development but also after completion of ocular develop-
ment in both the mouse and the human. 
In humans, we could detect strong signal of presence of PAX6 protein in the 
retina, cornea and lens of human fetus until birth. PAX6 presence was also 
established in the inner retina layers from adult patients ranging form 20 to 79 
years old of age. There were some differences in PAX6 expression among pa-
tients but that was partly explained protein denaturation depending of tissue 
time collection after death. Pax6 was more specifically expressed in the inner 
layers of the retina: the inner ganglion and the bipolar cell layers of the retina 
and the amacrine cells. The presence of PAX6 gene and its products PAX6 in 
the adult and fetal human eye are in agreement with previous studies performed 
on human and monkey.52 
It was surprising to discover that a gene such as Pax6 dedicated to the ocu-
lar development was still present and properly expressed 79 years after the end 
of the ocular development. To the best of our knowledge, we found only few 
other development genes still expressed in adulthood, for example, Fox tran-
scriptor factors, are primordial for liver organogenesis but do also play a role in 
liver function after birth throughout adulthood.53 Perhaps, PAX6 gene might also 
take part in the regulation, function and protection of the eye and the retina after 
birth. 
PAX6 is also expressed in the corneal and conjunctival epithelium of adult 
chicken and monkey. It is expressed in these mitotically active and regenerating 
tissues through life, and abnormal expression may cause progressive corneal 
dystrophy. PAX6 was believed to play a direct role in the maintenance and pro-
liferation of corneal stem cells, a vital process that appears to be defective in 
aniridia.54 Human adult corneal epithelial cells expressed also Pax6 gene.54 
PAX6 overexpressing corneal epithelial cell lines disclosed inhibition of cell 
proliferation on cell cultures, confirming the notion that PAX6 plays a role in 
controlling corneal epithelial cell dynamics in vivo.55 Heterozygous small eye 
mice demonstrated compromised cellular adhesion of the corneal epithelium 
suggesting a role for Pax6 in the proper generation and maintenance of the 
adult cornea.56 In humans, corneal pannus tissues from patients with different 
ocular surface diseases were disclosing a decline or absence of PAX6 expres-
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sion while normal ocular surface epithelial cells showed regular PAX6 expres-
sion.57 PAX6 expression is increased in the corneal epithelium during wound 
healing after experimental injury. PAX6 is up regulated during repairing corneal 
epithelium, it controls the activity of the gelB promoter that regulates matrix 
metalloproteinases (MMPs) which act as morphogenetic regulators in embry-
onic and adult events of tissue remodeling. These results indicate that PAX6 
helps to maintain the normal corneal epithelial phenotype postnatally, and that 
down-regulation of Pax6 is associated with abnormal epidermal differentiation in 
severe ocular surface diseases. Reintroduction of activation of the Pax6 gene 
might be useful in treating squamous metaplasia of the ocular surface epithe-
lium.58 All these observations suggested that PAX6 may be actively involved in 
coordinating adult cornea organization and repair mechanism. 
Pax6 expression in mouse models of retinal degeneration 
Pax6 seem to play an important role in different mechanism of retina regenera-
tion involving stem cell and retina progenitor cells. In the zebrafish, PAX6A and 
PAX6B proteins are required at different points in neuronal progenitor cell pro-
liferation and differentiation derived from Müller glial-derived neuronal progeni-
tor cell during retinal regeneration after light exposure.59 Likewise, mice with 
acquired or inherited retinal degeneration disclosed an increasing number of 
retinal precursors cell expressing Pax6 gene in the pars plana in response to 
retinal damage. Some of these cells differentiated from proliferating cells even 
after formation of the adult retina.60 Interestingly the human retina does not 
share the plasticity to regenerate neurons as in goldfish and quail, but recent 
reports have demonstrated that some cells at the margin of the retina and in the 
pars plana, are capable of regenerating and inducing proliferation of retina 
cells.61 These retinal progenitor cells (RPCs) have been also localized in the 
adult ciliary epithelium. These RPCs can differentiate into glial and retina cells 
expressing markers characteristic of other progenitor cells and seen during 
early retinal development such as Pax6 gene. The RPCs could become a future 
source of stem cells and retina cell transplantation in the future for the treatment 
of retinal degeneration.62 
In view of these studies and the presence of Pax6 in the adult inner retina, 
we assumed that Pax6 might play a role into the maintenance and defense 
mechanism of the retina. 
It is difficult to obtain in vivo results of Pax6 expression in the retina after 
retinal injury or aggression. Therefore, we looked at the behavior of Pax6 in the 
adult mice retina a different ages as we did with the human and also in degen-
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erative retina conditions. We studied the expression of Pax6 in both induced 
and genetically acquired retina degeneration. Light-induced retinal degeneration 
shows signs of apoptosis 24h immediately after exposure and complete disap-
pearance of the outer nuclear layer with one month. Rd1 mice, lack the beta 
subunit of PED. They show a progressive retinal degeneration that starts 8 day 
after birth and last up to two months until complete absence of the photorecep-
tor layer. 
We found that PAX6 protein still present in elderly wild type mice up to 429 
days old. PAX6 protein expression was stronger in the first month and reduced 
progressively after, but remain expressed throughout adulthood. In both human 
and mice, PAX6 was found to be expressed in the inner layers of the retina and 
more specifically the inner ganglion and the bipolar cell layers of the retina. 
These findings are in accordance with previous reports that have studied Pax-6 
transcripts were detected in the ganglion cell- and amacrine cell layers of the 
retina at days 3, 10, 17 and 31 posthatching and in 2- to 3-month-old chick ret-
ina by in situ hybridization.63 They suggested that known association of PAX6 
expression with proliferation and emergence of different cell types such as gan-
glion and inner nuclear cell layers may retain proliferative potential for an ex-
tended period in the young adult retina. 
In Pde6b(rd1) mouse, the outer nuclear layer, and more precisely the photo-
receptors cells die by apoptosis and reach their peak between p10 and p14. We 
found that during exactly the same period, PAX6 expression was decreased on 
Western Blot analysis of retina tissue extracted from Pde6b(rd1) mice. On Im-
munohistochemistry PAX6 was confined to the ganglion and to the bipolar cell 
layer of the retina; there were no PAX6 expressing cells in the outer layers of 
the retina. At p21, PAX6 protein levels returned to levels similar than p6 and p8 
and kept the same expression level until p28. We could not keep a sufficient 
number of Pde6b(rd1) mice alive to study Pax6 expression throughout their 
lifespan in older age. We could not therefore conclude whether there is a causal 
relationship between apoptotic cell death of photoreceptors and reduced ex-
pression of Pax6 in the inner retina. These results suggest that a decrease of 
PAX6 protein expression is concomitant to the peak of photoreceptor apoptosis. 
One might speculate therefore, that Pax6 might have a protection role against 
photoreceptor death. Interestingly, there is evidence of inter-cellular signaling 
pathways between the inner and outer retina. Indeed, intraocular injection of 
neurotrophic factors can promote the survival of retinal photoreceptors in differ-
ent animal models for retinal degeneration while corresponding cellular recep-
tors are exclusively found in the inner retina. Brain-derived neurotrophic factor 
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(BDNF) and ciliary neurotrophic factor (CNTF) exert their effect on photorecep-
tors by acting indirectly through activation of Muller cells64 More recently, it was 
found that VEGF stimulates the proliferation of RPCs (Retinal Progenitor Cells) 
through VEGFR2/Flk1 located in the retina of Pde6b(rd1) mice.65 The observed 
proliferation of RPCs expressing Pax6 detaining the potential to differentiate 
into retinal neurons may enhance the regeneration of the degenerating retina. 
VEGF decrease started at p9, coinciding with the beginning of retinal photore-
ceptor apoptosis, whereas VEGF expressing cells were located in the INL and 
GCL layers of the retina. Photoreceptor death was correlated with a decrease of 
VEGF. Similarly, death of photoreceptor was also correlated with a decrease of 
PAX6 as if some vertical signals between inner and outer retina have been 
stopped. 
To confirm our hypothesis of a protective role of Pax6 in the degenerating 
retina, we analyzed Pax6 expression in wild-type (C3H background) mice ex-
posed to bright light and in c-fos knockout mice known to be resistant to retinal 
degeneration induced by light exposure. 
In agreement with our previous findings in Pde6b(rd1) mice, wild-type ani-
mals undergoing photoreceptor apoptosis after light exposure disclosed a de-
cline in PAX6 levels during degeneration whereas PAX6 levels were increased 
at 2 and 6 hours after illumination in protected c-fos knockout mice.66 The de-
crease of Pax6 expression at the peak of apoptosis in Pde6b(rd1) mouse and 
its increase in the c-fos-/- mice resistant to light induce retinal degeneration are 
both suggestive of a protective role played by Pax6 in the maintenance and 
function of the adult retina exposed to aggression. 
In conclusion, we show that downregulation of Pax6 is concomitant with in-
herited and induced retinal degeneration whereas animal models protected 
against induced retinal degeneration demonstrate an increase of Pax6 levels. 
One might speculate that the level of Pax6 expression might be a co-factor that 
should be taken into consideration in the chain of events leading to degenera-
tive retinal disease. 
Nevertheless, further studies investigating the intercellular pathways be-
tween dying photoreceptor and inner retina cells are required to increase our 
understanding of the putative protective role of Pax6 in the retina. 
How Pax6 expressing cells located in the inner nuclear layer communicate 
with photoreceptors remains to be elucidated? It might be also possible that 
during any aggression, retinal Müller glial cell dedifferentiate to produce RPC 
depending on Pax6 levels. These RPC are probably able to lead to formation of 
any other retina cells with their respective specific markers. 
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Pax6 expression in a mouse model of glaucoma 
Because, Pax6 expressing cells were mainly located in the inner layers of the 
retina, we were curious to investigate Pax6 expression in a mouse model affect-
ing specifically the inner layer of the retina. Therefore, we compared Pax6 ex-
pression by WB, IHC and RT-PCR in the retina of wild-type and CLRSMαA (calci-
tonin receptor-like receptor) transgenic mice. Expression of calcitonin receptor-
like receptor is under the control of a smooth muscle alpha-actin promoter in 
these mice and results in increase signaling of the smooth-muscle-relaxing pep-
tide adrenomedullin in the pupillary sphincter muscle that leads to pupillary 
palsy and angle closure glaucoma.67 CLRSMαA mice develop angle-closure glau-
coma after completion of retinal development and progressively disclosed loss 
of retinal ganglion cell at p42 and loss of inner nuclear layers cells around p62. 
Our results showed a decreased of PAX6 expression in the GCL of CLRSMαA 
mouse during the initial phase of ganglion cell degeneration. At p82, despite 
severe loss of ganglion cells, INL cells from CLRSMαA mice displayed a marked 
increase in PAX6 protein levels. At this time point, the ganglion cell layer has 
lost about 75% of its cells disrupting therefore the synaptic connectivity between 
bipolar-, amacrine- and ganglion cells. This increase in PAX6 protein could be 
related to remodelling process occurring in retinal degeneration. Indeed,the 
space left by degenerating ganglion cells in retinitis pigmentosa is occupied by 
Müller that increase their production of intermediate filaments.68 
Since Pax6 regulates eye development including retinal morphogenesis,52 it 
is conceivable that increased Pax6 production during degeneration is required 
for surviving cells to adapt to the altered conditions by changing their cytoarchi-
tecture. This assumption has been supported by over-expresssion and under-
expression experiments of Pax6 gene responsible for different ocular abnor-
malities. 
Taken together, our data show that retinal ganglion cell death induces the 
expression of Pax6 in cells of the INL. This suggests that Pax6 might be in-
volved in the maintenance of the cellular integrity after the loss of synaptic con-
nectivity and/or in processes required for the remodelling of the retinal cytoar-
chitecture after ganglion cell loss. 
In view of all these findings, we assumed that Pax6 is a major actor of retina 
maintenance and protection during adulthood. 
To explore and define the role of Pax6 in the adult retina, it would be inter-
esting to suppress Pax6 gene totally or partially in a definite well-formed adult 
retina. Pax6 knockout mice are lethal shortly after birth. Therefore, we are cur-
rently building an inducible Cre/Lox Pax6 knock-out mouse. The suppression of 
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Pax6 in an adult mammalian would shed some light of PAX6 implications in the 
adult retina. 
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Summary 
Summary 
Summary 
PAX6 gene is a member of PAX gene family which has a major role in the for-
mation of tissues and organs during development. PAX6 gene encodes PAX6 
protein, a transcriptor factor, acting in the formation of specific organs such as 
the pancreas, the spinal cord, the brain, the olfactory nerve and the eye. 
PAX6 gene is also known as aniridia gene in humans where it was cloned. 
PAX6 protein is composed of two DNA-binding domain, a paired domain 
and a homeodomain. Through DNA binding, PAX6 control the expression of 
various genes involved in complex regulatory networks in the eye. 
Human homozygous PAX6 mutation is lethal shortly after birth resulting in 
anopthalmia and severe brain malformations. Heterozygous mutations of PAX6 
lead to a constellation of pathologies comprising both the anterior and the pos-
terior segment of the eye. They include aniridia, autosomal dominant keratatis, 
Peters anomaly, juvenile cataract, glaucoma, isolated foveal hypoplasia, mi-
crophthalmia, ectopia pupilla, optic disc coloboma, optic nerve hypoplasia and 
morning glory disc anomaly. 
PAX6 gene and its expression are both remarkably conserved throughout 
evolution, to the point that PAX6 homolog of Drosophila has more than 90% 
sequence similarity with human PAX6 gene. Small eye gene (Sey), is the mur-
ine homolog of PAX6. Like in humans, homozygous mutation is lethal in mice 
and heterozygous mutations result in a variety of phenotypes similar to human 
abnormalities. 
Exact dosage of PAX6 gene during development is required for normal eye 
formation. Over expressions of PAX6 gene, as much as underexpression, in 
mouse and human is also responsible for severe eye pathologies. Similarly 
when Eyeless gene, the Drosophila homolog of human PAX6, is injected into 
the imaginal disc of the developing Drosophila, it induced ectopic expression of 
eyes on the antennae, wings and thorax. 
The fundamental role played by PAX6 in eye formation during development 
and its capacity to trigger activation of a cascades of genes in a coordinated 
fashion, leading to the development of the eye have lead scientists to call 
PAX6, the master gene for eye formation. 
Despite extensive knowledge of PAX6 gene and its protein during develop-
ment, little is known about its role in the adult after the end of ocular develop-
ment. 
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It has been hypothesized that PAX6 may intervene in the maintenance and pro-
tection of adult eye tissues. We were therefore interested to study PAX6 ex-
pression in the adult retina of both human and mouse. 
We found that PAX6 is expressed at all ages of adulthood in the human ret-
ina up to 79 years. PAX6 was predominantly located in the ganglion cell layer 
and in the inner layer of the retina. 
Likewise, we found that PAX6 was expressed in the inner layers of the 
mouse retina up to 428 days (an old age for a mouse!). 
We showed that PAX6 expression was reduced during the peak of photore-
ceptor apoptosis in rd mouse, a mouse model of retinitis pigmentosa. Similarly, 
wild-type mice disclosed decreased PAX6 expression in the retina of light-
induced retinal degeneration mice. Conversely, PAX6 expression was in-
creased in c-fos knock-out mice showing resistance to light induced retinal de-
generation. 
In a mouse model of acute angle-closure glaucoma, CLRSMαA mouse, in-
traocular pressure increased between p22 to p82 to over two times higher lev-
els than in control mice resulting in apoptosis of the cells of the inner retina. We 
showed that there was first, a progressive decrease in cell number of the inner 
retina including PAX6 expressing cells in the ganglion cell layer. Later, a signifi-
cant increase of PAX6 expressing cells concomitant with an overall loss of cells 
was observed in the inner retina layer of CLRSMαA mouse. 
Our results confirmed that PAX6 was found in both healthy and degenera-
tive adult mammalian retina. These findings were in accordance with the pres-
ence of PAX6 in adult cornea of mice and humans. PAX6 helps to maintain the 
normal cornea phenotype and plays an important role during repair of corneal 
epithelium in case of physical aggression. 
We speculated that PAX6 has a protective role in the degenerating outer 
retina through an activation of Müller glial cells who might be capable to pro-
duce retinal progenitor cells and hence all 
In the same manner, when ganglion cell layer is massively disrupted in 
CLRSMαA mouse, there was an increase of PAX6 INL expressing cells that could 
be related to remodeling process involving Müller cells. 
We assumed that PAX6 plays a crucial role in the maintenance and protec-
tion during adulthood. 
To confirm our hypothesis, it would be interesting to suppress PAX6 gene in 
an adult retina. Since PAX6 knockout mice are lethal right after birth, inducible 
PAX6 knock-out mice would be an elegant solution to investigate the exact 
function of PAX6 after the end of ocular development. 
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Samenvatting  (Summary in Dutch) 
Samenvatting 
Het PAX6-gen behoort tot de PAX genfamilie, die een belangrijke rol speelt bij 
de vorming van weefsels en organen gedurende de embryonale ontwikkeling. 
Het PAX6-gen codeert voor het PAX6-eiwit, een transcriptie factor,die actief 
betrokken is bij de vorming van specifieke organen zoals de pancreas, het rug-
genmerg, de hersenen, de oogzenuw en het oog. 
Het PAX6-gen staat bij de mens ook bekend als het aniridie gen vanwege 
het feit dat het als kandidaat gen voor deze ziekte werd gekloneerd. 
Het PAX-6 eiwit bestaat uit twee DNA-bindende domeinen, een “Paired 
domein” en een “Homeodomein”. Door binding aan het DNA controleert PAX6 
de expressie van verschillende genen die betrokken zijn bij complexe regelnet-
werken in het oog. 
Bij de mens is homozygotie voor de PAX6 mutatie kort na de geboorte le-
thaal. Deze gaat gepaard met anophthalmie en ernstige hersenafwijkingen. 
Heterozygote mutaties van PAX6 leiden tot een combinatie van oogafwijkingen 
die zowel de voorste als de achterste oogkamer kunnen omvatten. Deze betref-
fen onder andere aniridie, autosomaal dominante keratatis, Peters anomalie, 
juveniele cataract, glaucoma, geïsoleerde foveale hypoplasie, microphthalmie, 
ectopia pupilla, optische papil coloboom, oogzenuw hypoplasie and morning 
glory papil. 
Het PAX6 gen en de expressie ervan zijn opmerkelijk geconserveerd tijdens 
de evolutie. Zo is er meer dan 90% overeenkomst tussen de gensequentie van 
de PAX6 homoloog bij Drosophila en de volgorde van het PAX6 gen bij de 
mens. Small eye gene (Sey) is het homologe gen van PAX6 bij de muis. Beide 
genen vertonen grote overeenkomsten. Ook bij de muis is de homozygote mu-
tatie lethaal terwijl de aanwezigheid van heterozygote mutaties leidt tot een 
scala aan afwijkende fenotypes dat veel gelijkenis vertoont met dat bij de mens. 
Voor een normale oogontwikkeling is een exacte dosering van de PAX6 
gen-expressie gedurende de embryonale ontwikkeling vereist. Zowel over- als 
onderexpressie van het PAX6-gen, zijn zowel bij muis als mens verantwoorde-
lijk voor de vorming van ernstige oogafwijkingen. Ook leidt de injectie van het 
Eyeless gen, dat het homologe gen van PAX6 bij Drosophila is, in groepjes 
ongedifferentieerde cellen van Drosophila larven, tot ectopische expressie en 
de vorming van ogen op de antennen, de vleugels en de thorax. 
S a m e n va t t i n g  
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De fundamentele rol die PAX6 speelt bij de oogontwikkeling tijdens de embryo-
nale ontwikkeling en het vermogen om een cascade aan genen, en daarmee de 
oogontwikkeling, op een gecoördineerde manier te activeren heeft ertoe geleid 
dat PAX6, het “master” gen voor de oogontwikkeling wordt genoemd. 
Ondanks het feit dat veel bekend is over de rol van het PAX6-gen en zijn 
eiwit gedurende de embryonale ontwikkeling is weinig bekend over de rol bij de 
volwassene na het afsluiten van de oogontwikkeling. 
Men heeft verondersteld dat PAX6 betrokken zou kunnen zijn bij het hand-
haven en beschermen van de weefsels in het volwassen oog. We waren daar-
om geïnteresseerd om de PAX6 expressie te bestuderen in de volwassen retina 
van zowel mens als muis. 
We vonden daarbij dat PAX6 expressie bij de mens kan worden waarge-
nomen op alle leeftijden (tot en met 79 jaar). PAX6 was vooral gelokaliseerd in 
de ganglion cellaag en de binnenste laag van de retina. 
Overeenkomstig hiermee werd bij de muis waargenomen dat PAX6 tot ex-
pressie kwam in de binnenste lagen van muis retina van de muis tot op een 
leeftijd van 428 dagen (hetgeen erg oud is voor een muis!). 
We hebben aangetoond dat PAX6 expressiegereduceerd was tijdens de 
piek van de phoreceptor apoptose in de rd muis, het muismodel van retinitis 
pigmentosa. Overeenkomstig hiermee lieten wild-type muizen een verlaagde 
PAX6 expressie zien in de retina of licht-geïnduceerde retinale degeneratie. 
Daar staat tegenover dat de PAX6 expressie was toegenomen in c-fos knock-
out muizen die weerstand tonen tegen licht-geïnduceerde retinale degeneratie. 
In een muis model van acuut kamerhoek glaucoom, de CLRSMαA muis, was 
de intraoculaire druk toegenomen van p22 tot p82 tot twee keer hogere waar-
den dan in controle muizen hetgeen apoptose van cellen in de binnenste retina 
tot gevolg had. We hebben aangetoond dat er eerst sprake was van een pro-
gressieve afname van het aantal cellen in de binnenste retina waaronder ook 
de PAX6 expresserende cellen van de ganglioncellaag. Later, was er een signi-
ficante toename van de PAX6 expresserende cellen tegelijk met een verlies van 
cellen in de binnenste retina laag van de CLRSMαA muis. 
Onze resultaten bevestigen dat PAX6 zowel aanwezig is in de gezonde als 
in de degeneratieve retina van volwassen zoogdieren. Deze bevindingen ko-
men overeen met de aanwezigheid van PAX6 in de cornea van volwassen mui-
zen en mensen. PAX6 helpt bij het handhaven van het normale cornea fenoty-
pe en speelt een belangrijke rol tijdens het herstel van het cornea epitheel in 
geval van fysieke beschadiging. 
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We veronderstellen PAX6 een beschermende functie heeft in de degenereren-
de buitenste retina door een activatie van Müller glia cellen die in staat zouden 
kunnen zijn retinale voorloper cellen te produceren. 
Op dezelfde manier werd waargenomen dat wanneer de ganglion cellaag 
ernstig beschadigd werd in de CLRSMαA muis, er sprake was van een toename 
van PAX6 INL expresserende cellen hetgeen verband kan houden met de be-
trokkenheid van Müller cellen bij dit remodeling proces. 
We nemen aan dat PAX6 een cruciale rol speelt bij het handhaven en be-
schermen bij volwassenen. 
Om deze hypothese te bevestigen zou het interessant zijn om het PAX6-
gen te onderdrukken in de volwassen retina. Omdat PAX6 knockout muizen 
kort na de geboorte lethaal zijn, zouden induceerbare PAX6 knock-out muizen 
een elegante oplossing kunnen bieden bij het onderzoek naar de exacte functie 
van PAX6, na het afsluiten van de oogontwikkeling. 
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